Kilogram Scale Synthesis of a Triazine-based Dendrimer and the Development of a General Strategy for the Installation of Pharmacophores to Yield Potential Drug Delivery Agents by Venditto, Vincent J.
  
KILOGRAM SCALE SYNTHESIS OF A TRIAZINE-BASED DENDRIMER AND 
THE DEVELOPMENT OF A GENERAL STRATEGY FOR THE 
INSTALLATION OF PHARMACOPHORES TO YIELD POTENTIAL DRUG 
DELIVERY AGENTS 
 
 
A Dissertation 
by 
VINCENT JOSEPH VENDITTO  
 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of  
DOCTOR OF PHILOSOPHY 
 
 
December 2009 
 
 
Major Subject: Chemistry 
  
KILOGRAM SCALE SYNTHESIS OF A TRIAZINE-BASED DENDRIMER AND 
THE DEVELOPMENT OF A GENERAL STRATEGY FOR THE 
INSTALLATION OF PHARMACOPHORES TO YIELD POTENTIAL DRUG 
DELIVERY AGENTS 
 
A Dissertation 
by 
VINCENT JOSEPH VENDITTO  
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of  
DOCTOR OF PHILOSOPHY 
 
Approved by: 
Chair of Committee,  Eric E. Simanek 
Committee Members, Brian T. Connell 
 Marcetta Y. Darensbourg 
 Gerard L. Coté 
Head of Department, David H. Russell 
 
December 2009 
 
Major Subject: Chemistry
  
iii 
ABSTRACT 
Kilogram Scale Synthesis of a Triazine-Based Dendrimer and the Development of a 
General Strategy for the Installation of Pharmacophores to Yield Potential Drug 
Delivery Agents. (December 2009) 
Vincent Joseph Venditto, B.S., Gettysburg College 
Chair of Advisory Committee: Dr. Eric E. Simanek 
 
 Diverse dendrimer peripheries are often produced through convergent synthesis 
with multiple protection-deprotection steps.  Achieving such diversity while maintaining 
monodispersity has previously proven problematic.  Interception of an electrophilic 
poly(monochlorotriazine) dendrimer with a molecule of interest bearing a reactive, 
nucleophilic group presents an efficient method to achieve large quantities of dendrimers 
with biologically relevant peripheries.   
Kilogram-scale synthesis of a triazine-based dendrimer relies on reaction of the 
dichlorotriazine monomer with the amine terminated dendrimer to afford a 
poly(monochlorotriazine) dendrimer.  Normally, the dendrimer is then reacted with 
piperidine, an inexpensive “cap” due to its chemically inert nature after reaction.  The 
dendrimer then undergoes a global deprotection to afford an amine-terminated 
dendrimer.  Subsequent iterations with the dichlorotriazine monomer affords higher 
generation architectures.  Intercepting the poly(monochlorotriazine) dendrimer with 
biologically relevant molecules containing reactive amines enables the development of a 
drug delivery vehicle.  Desferrioxamine B, an iron chelate, and camptothecin, and anti-
cancer drug, are two clinically approved drugs of interest investigated for 
macromolecular drug delivery.  Upon acylation of each drug with BOC-isonipecotic 
acid, substitution on the dendrimer may occur with varying levels of success depending 
on the drug in question. Upon successful substitution to afford the desired product, 
biological studies may be performed. Each synthetic approach will be discussed along 
with alternative routes leading to this general strategy.   
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CHAPTER I 
INTRODUCTION 
 
1.1 The Evolution of Dendrimers   
During the early 1900’s polymers became a major interest within the field of 
chemistry.  Theoretical contributions from Staudinger1 and experimental evidence of 
Carothers2 paved the way for further advancements toward the development of 
polymerization catalysts by Ziegler3 and Natta4 and polymerization kinetics by Flory.5  
More recently, the development of “living” polymerization techniques have dcreased 
polydispersities toward the achievement of monodisperse architectures.6, 7 However, 
improvements in linear polymerizations did not translate directly to branched polymers.  
The development of crosslinked and hyperbranched polymers showed many of the 
properties of linear polymers and improved structural properties but suffered from high 
polydispersity.  The inability of simple branched olefins to undergo controlled reactions 
was due to the lack of differential reactivity between reactive centers.  Such challenges 
opened the field to the development of dendrimer chemistry in the late 1970’s. 
Generally, polymerizations occur through addition of monomer and reagents to a 
single reaction vessel.  The products obtained oftentimes have a wide range of molecular 
weights and structures.  The inability to accurately characterize or purify the products 
leads to potential ambiguity in determining the mechanisms of action when used in 
biomedical applications.  The ability to produce monodisperse polymers provides 
regulatory advantages, as well as advantages in deciphering complex mechanisms upon 
specific tailoring of molecules.   
Typically, linear polymers grow in two directions with two terminal reactive 
units.  Alternativelly, hyperbranched polymers achieved through the use of branched 
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monomer units generates a large number of terminal functionalities depending on the 
feed ratios of the monomer units.  The development of dendrimers with exceptionally 
low polydispersity required monomer units with the ability to initiate and polymerize 
selectively.  Such monomers were developed through the use of differential reactivity or 
protecting groups to achieve the desired products.  Figure 1.1 summarizes different 
polymerization techniques through the use of cartooned puzzle pieces for monomer 
units.  Each terminal functional group (arrow) may react with its corresponding acceptor 
functionality (inverted arrow) to form polymers.  Thus, as shown here, polymerization of 
linear polymers propagates when both monomers are present.  
1. Deprotect
2.
A)
B)
C)
 
Figure 1.1: Cartoon summary of the synthesis of: A) linear polymers, B) hyperbranched 
polymers and C) dendrimers. 
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The dendrimer synthesis uses protecting groups as cartooned with caps on the arrows to 
prevent hyperbranching.  Subsequent iterations of monomer addition and deprotection 
produce higher generations.  The generation of a dendrimer is classified as the number of 
synthetic iterations performed.  Therefore, when using a monomer that branches into two 
terminal groups, three “arrows” present on the core become six at the first generation. 
The second-generation dendrimer then has twelve “arrows” or terminal functional 
groups and so on. 
While polymerization has been a flourishing field for over 100 years, the 
development of new monomer units spawned the area of dendrimer chemistry which 
continues to grow today.8  Originally, these well-defined branched structures were 
known as cascade polymers,9 but later adopted the names arborols10 and dendrimers.11  
Vögtle first synthesized cascade polymers in 1978 as pseudo-cavities for ion binding.9  
The synthesis employed a core molecule with three reactive sites, which could undergo 
iterative synthetic steps to introduce the branches.  This synthetic strategy became 
known as the divergent method of synthesis, which was later utilized by Denkewalter,12 
Newkome10, 13-15 and Tomalia11, 16-21 in the 1980’s.  The tree-like structure of the 
molecules suggested the name dendrimer, from the greek dendros, meaning tree.  This 
new class of macromolecules quickly found utilization through functionalization of the 
multivalent periphery with “leaves” to generate macromolecular constructs for a variety 
of potential applications from medicine to materials science.   
Poly(amidoamine) (PAMAM) dendrimers were the first constructs synthesized, 
which classified these new architectures as dendrimers.11  The PAMAM dendrimers 
were synthesized through Michael addition with methyl acrylate and ethylene diamine 
from a core outward to form a water soluble polyamide architecture.  The route of 
growth from the core outward is known as the divergent route.  The scalablity of this 
dendrimer and ease of synthesis enabled commercialization and further exploitation.  
Initially, dendrimers showed copper sequestration ability22 and were later exploited for 
radioimmunotherapy and imaging when decorated radionuclide or gadolinium 
complexes.23, 24  However, shortly after the first report of PAMAM dendrimers, the 
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attempted synthesis of other architectures proved to be less successful due to significant 
challenges in purification arising from imperfections at higher generations.  To 
overcome such drawbacks, a new synthetic technique was developed, which utilized the 
same concept, but built the dendrimer from the periphery inward.25-27  This route was 
termed the convergent route.  The two synthetic routes as well as the development of 
new monomer units and core molecules improved the synthetic efficiency and provided 
great potential toward macromolecules with interesting properties. Various other 
dendrimer architectures have been developed since the mid 1980’s including new 
poly(amides),28 phosphorous-based dendrimers29, 30 and polyaryl dendrimers31, 32 to 
name a few. 
1.2 Polymer Therapeutics 
Polymer therapeutics is a burgeoning field33-36 that combines the therapeutic 
capabilities of small molecule drugs with the extended blood retention times of 
macromolecules.  Namely, in cancer, polymers are designed to exploit tumor 
physiology37, 38 and achieve improved efficacy.  Small molecule drugs are chosen for 
incorporation into polymer therapeutics due to the various limitations of efficacy that 
would retard clinical application including: 1) poor solubility, 2) rapid clearance, 3) high 
systemic toxicity and 4) poor selectivity to the site of treatment.39  Each of these 
limitations may be addressed through covalent or non-covalent attachment to polymer 
architectures.  Accordingly, dendrimer based constructs present new possibilities to treat 
a variety of diseases.  
Two notable features of polymers keep them at the forefront of therapeutic 
applications, namely their size and multivalency.  Dendrimers have the additional benefit 
of monodispersity, which enables production of exact entities for biological evaluation.  
Dendrimers are on the scale of proteins and display a large number of peripheral groups 
for functionalization.  Multivalency is useful in nature for a number of processes ranging 
from cell-cell interactions to viral infections.40  Viruses, like dendrimers are large and 
have a multivalent periphery.  Their size helps them to remain in the blood stream for 
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extended periods, while their multivalency aids in improving infection through enhanced 
ligand-receptor interactions.  Previously, multivalency was exploited in dendrimers for 
HIV sequestration,41 investigation of protein-cell interactions42 and magnetic resonance 
imaging24 among other areas.  Dendrimers may also utilize their size for enhanced blood 
retention, and their multivalency for high drug loading capacity.  Generally, small 
molecules are filtered quickly from the blood stream by the kidneys and are excreted 
rapidly within the urine or are converted to inactive metabolites.  Through attachment of 
drugs to dendrimers, high drug loading is possible, with improved solubility and 
extended plasma half-life.  
Polymeric therapies for cancer therapy have witnessed a significant amount of 
attention in recent years for the reasons mentioned above.  More specifically, however, 
in cancer therapy one of the major challenges is tumor localization, causing damaging 
side effects to other organs.  Through increased blood circulation and “leaky” 
vasculature at the site of the tumor, localized tumor therapy may be realized.  The 
extended circulation and tumor accumulation has been termed the enhanced permeability 
and retention (EPR) effect.37  The exploitation of physiology for improved therapy, 
however, may only be achieved after selection of the dendrimer platform best suited for 
the application.  As we strive to develop dendrimers for biomedical applications, the 
proper selection of monomer and peripheral units enable us to achieve high molecular 
weights with improved pharmacokinetics. 
 
1.3 Triazine-Based Dendrimer Synthesis 
While dendrimers are more monodisperse than their original hyperbranched 
polymer counterparts, many of the constructs discussed have suffered from 
imperfections and complications during synthesis.  The ability to synthesize new 
dendrimer architectures, which are easily synthesized with robust high yielding reactions 
for eventual scalable synthesis and commercialization are still desired, to more 
effectively produce a macromolecular architecture for affordable medicine.  Our efforts 
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toward the scalable synthesis of monodisperse architectures, which are easily 
manipulated, began approximately ten years ago and continue today.   
The commercial use of dendrimers for a variety of applications depends on the 
cost and scalability, which are determined by the synthetic ease of each reaction, the 
robust nature of the reactions and the cost of starting materials among other parameters.   
Each dendrimer mentioned above has been synthesized to address each of these aspects 
to varying levels of success, but maximum optimization derives from an educated 
selection of core, monomer and peripheral unit as well as the synthetic route employed.  
The possibility for infinite combinations makes the selection of each unit a cumbersome 
task.  Herein, we aim to provide clarity toward our choice of synthetic route, core and 
branching units, which led to the kilogram-scale synthesis of a second-generation 
triazine-based dendrimer.  En route to achieving this goal we synthesized a number of 
dendrimers, which enabled us to better understand the reactivity and continue to 
optimize our strategy.  The reactivity and advantages of each unit and reaction sequence 
are summarized in the following section devoted to advancements in triazine-based 
dendrimer synthesis.   
1.3.1 Triazine and Nucleophilic Amine Reactivities 
A limited number of triazine-based polymeric architectures had previously been 
reported in the literature prior to 2000.43-46  Of the published reports, however, many 
employ a nitrile cyclization to obtain the triazine ring.  This method is applicable when 
synthesizing symmetric molecules, however, expanding this chemistry into the synthesis 
of complex asymmetric architectures containing a diverse periphery affords a mixture of 
products.  To overcome such shortfalls of nitrile cyclization to obtain similar structures, 
the chemoselective reactivity of cyanuric chloride using nucleophilic aromatic 
substitution may be exploited.  This enables one to synthesize such molecules with quite 
diverse peripheries and a limitless potential for eventual applications.  Taking cues from 
the functionalization of cyanuric chloride in the late 1800’s by Fries,47, 48 we are able to 
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achieve macromolecular architectures with high monodispersity on large scale and in 
modest yield.   
Cyanuric chloride is an attractive molecule for dendrimer synthesis due to the 
low cost and chemoselective reactivity.49  The generally accepted reactivity trend, as 
shown in Scheme 1.1, proceeds at 0 °C for the first substitution while the second and 
third substitutions occur at 25 °C and 70 °C, respectively.50 
Scheme 1.1: General reactivity of chlorotriazines with amine nucleophiles. 
 
While this scheme explains the electrophilic differences between 
trichlorotriazines, dichlorotriazines and monochlorotriazines, abbreviating the 
nucleophile with an “R” group prevents the full comprehension of such reactions.  The 
differences in amine reactivity enable further control over the generalized reactivity 
trend and allows for more efficient and robust dendrimer synthesis.  To develop an 
understanding of the differential amine reactivity, monochlorotriazines were reacted 
with a variety of amines.  The products were quantified over time using NMR to 
generate the following series and associated relative reactivity values (Figure 1.2).50, 51  
H
N
H
N
H
N
H
N
N
H
N NH
N
H
N
O
H
N
NH2 H
N
NH2
321       214        64         45         32         21        10              7            3         2           1  
Figure 1.2: Relative reactivity of a series of amines toward monochlorotriazines. 
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The differential reactivity of amines has great impact in the synthesis of our 
dendrimers and enables us to perform reactions on the dendrimer, in some cases, without 
the use of protecting groups.52 We have expanded on the general trend of chlorotriazine-
based chemistry in Table 1.1.  The trend follows a pattern of cyclic secondary amines > 
primary amines > linear secondary amines > anilinic amines.  
Table 1.1: Generalized reactivity trend of nucleophilic amines toward chlorotriazine 
derivatives. 
 
This reactivity series can be explained using pKa, sterics and orbital 
characteristics.  Firstly, the pKa of anilines are approximately 5.0, while most other 
amines used in this study range from 8.0 to 11.0 suggesting that pKa would have an 
effect, however, the differences in relative reactivity between pyrrolidine (214, pKa = 
11.27) and piperidine (64, pKa = 11.22) would not be expected.51  Additionally, sterics 
may decrease reaction rates as seen in the low reactivity of diethylamine (2, pKa = 
10.64), which has comparable reactivity to that of butylamine (3, pKa = 10.59).  While 
the numerical differences here are not significant, the difference in reactivity from the 
cyclic to linear form is apparent.  Cyclic secondary amines are generally more reactive 
due to a combination of effects.  As the ring size decreases, the ring strain and the s-
orbital character increases, which is believed to cause an increase in orbital overlap with 
the electrophile and therefore increase the reaction rate.  The extent of each effect on the 
relative reactivity and their participation in reactivity is unclear, however, each effect 
must be considered in combination with each other when attempting to fully exploit this 
chemistry.  Our aim to exploit the differential reactivity of both amine nucleophiles and 
chlorotriazine electrophiles led us toward more efficient dendrimer syntheses.   
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1.3.2 Convergent vs. Divergent Synthesis 
Triazine dendrimers may be synthesized using a convergent route, divergent 
route or a combination of both to afford desired structures for specific applications.52  As 
explained previously, the convergent route involves synthesis of dendrons from the 
periphery inward, which are then joined to a core to afford the final dendrimer.  The 
divergent route, however, begins with a core and grows each branch outward generation 
by generation.  The convergent route benefits from a limited number of reactions 
occurring at each step, which generally remain the same throughout the synthesis, 
whereas the divergent route exponentially increases the number of reactions from 
generation to generation.  The convergent route enables complex functionalities to be 
obtained on the periphery while the divergent route generally requires that each 
peripheral unit be the same.  Due to the listed benefits, convergent syntheses are 
regarded as more efficient on the small scale, while divergent syntheses are used for 
kilogram-scale reactions.  Triazine-based dendrimers have been synthesized using both 
convergent and divergent routes successfully.  From our initial investigations in 
dendrimer synthesis, we aimed to expand our scope to implement a variety of core 
molecules, monomer units and peripheries to optimize the chemistry at each step, which 
eventually led us to our large-scale synthesis.   
 
1.3.3 Selection of Core, Monomer Unit and Peripheral Group 
Core molecules have been synthesized in our lab with functional groups 
numbering three or four, two examples are shown in Figure 1.3.  When the core 
contains four functional groups we refer to this as a “bow-tie”53 while three functional 
groups is a C3-symmetric core, formed from a triazine at the center with three diamine 
linkers appended from it. A variety of diamines have been employed including primary 
diamines, cyclic secondary diamines as well as mixed primary/secondary diamines.  
From the reactivity series, the cyclic secondary amines are more reactive and facilitate 
tri-substitution to afford the core in high yields at room temperature.  A core with three 
cyclic secondary amines exposed, also enables efficient addition of dichlorotriazine 
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monomer units at the first generation.  The tris-piperazinyl triazine core is commonly 
utilized in our syntheses due to cost, ease of core formation and easy addition of 
monomer units.  Amino-azetidine, however, was utilized as the core diamine molecule to 
form a tris-azetidine core with unique NMR signals, which was supplemented by 
aminopiperidine and aminopyrrolidine moieties at subsequent generations to better 
understand dendrimer motion and folding.54  The bow-tie core uses a diamine through 
which two triazine molecules are linked.  The synthesis of a bow-tie core involves 
additional synthetic steps to produce the monochlorotriazine, which is then coupled with 
a diamine.  While chemoselectivity of the bow-tie forming reaction is exploited, 
additional steps on the kilogram scale are undesirable.   
N
N
N
N
N N
NH
H
N
HN
NN
N
N
NN
N
N
N
NN
N
NH
NH
HN
HN  
Figure 1.3: The C3-symmetric core containing three terminal amines and the bow-tie 
core with four peripheral amines. 
From the core we add branching units to increase the multivalency.  Branching 
units are added iteratively to the core to produce successive dendrimer generations.  
Traditional polymer chemistry terminology classifies a linear symmetric bifunctional 
monomer unit as an AA monomer, which forms an -AAAAAA- polymer. An 
asymmetric unit, however, is classified as an AB monomer, which reacts with other 
monomer units to form an -ABABAB- polymer.  Due to the branching character of 
dendritic monomer units a similar terminology is applied.  In the case of triazine based 
branching units, a monochlorotriazine with two pendant amines is classified as an AB2 
monomer, while a monochlorotriazine with four pendant amines is classified as an AB4 
monomer as shown in Figure 1.4. 
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N
N
N
N
H
HN
Cl
N
N
N
N
N
Cl
NHBoc
NHBoc
NHBoc
NHBoc
NHBoc
NHBoc
 
Figure 1.4: Examples of an AB2 branching unit and an AB4 branching unit. 
Reaction of an AB2 unit with a C3-symmetric core affords a first generation with 
six terminal amines followed by twelve and 24 for the second and third generations as 
shown in Figure 1.5.  Likewise, a “bow-tie” dendrimer contains eight, 16 and 32 
terminal amines at the first, second and third generations, respectively. An AB4 
branching unit would then have twelve, 48 and 192 terminal groups at the first, second 
and third generations in the case of the C3-symmetric core and 16, 64 and 256 terminal 
amines for the bow-tie core, respectively.   
 
Figure 1.5: Second-generation dendrimer with C3-symmetric core and 12 terminal 
amines and a second-generation dendrimer with “bow-tie” core and 16 terminal amines.  
The core of each dendrimer is shown in black with first and second generation in red and 
blue, respectively. 
  
12 
Triazine-based dendrimers are synthesized through nucleophilic aromatic 
substitution and therefore our monomer units require an aromatic electrophile and 
protected amine nucleophiles.  The electrophile is the chlorotriazine moiety, which has 
remained consistent throughout our various dendrimers.  Our selection of nucleophiles, 
however, has evolved over time.  Initially, p-aminobenzylamine and piperazine were 
utilized, which enabled us to begin our investigations with dendrimer systems.  The 
hydrophobicity and rigidity of these molecules allowed us to study non-covalent drug 
sequestration, however certain applications required a less rigid system, which led to 
diamines including aminomethyl piperidine50 and diaminobutane,55 which are more 
flexible, producing a less rigid dendrimer. 
Recently, manipulation of the linker unit was exploited for the development of a 
library of dendrimers for gene transfection.  In the original library, a variety of core 
structures were utilized.  The cores included rigid structures containing piperazine linker 
groups; bowtie structures, which contain both piperazine and PEG-like diamine linkers 
and; flexible compounds, which contain a core having PEG-like diamine linkers.  While 
generation and peripheral groups were also varied in this library, the results from the 
biological studies indicated that the dendrimer core has the most profound affect on 
transfection efficiency, with the highest gene transfer seen for the flexible structures.56, 57   
The monomer unit for many of the dendrimers synthesized, including the family 
of transfection agents is a monochlorotriazine with two amines to form the AB2 
branching unit.  Monochlorotriazines, however, are less reactive electrophiles than their 
dichlorotriazine counterparts and require a more reactive nucleophile for substitution.  
While the diamines and monomer units utilized were of great importance to the 
advancement of our research, the ability to synthesize dendrimers using these building 
blocks on the kilogram-scale was less than desirable.  The need for more robust reactions 
was necessary, and thus a need for monomer units with increased reactivity.  
To increase electrophilicity, an amine nucleophile was necessary that could be 
added to cyanuric chloride to produce a dichlorotriazine containing two peripheral 
amines.  This was achieved successfully through use of a linear triamine with two 
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primary amines and a centrally located secondary amine.  The implementation of this 
molecule greatly improved the synthesis of our dendrimers allowing for complex 
dendritic architectures and efficient synthesis, which has led to the synthesis of 
kilogram-scale quantities of dendrimer.58, 59  Scheme 1.2 summarizes our synthesis and 
post-synthetic dendrimer modifications to obtain functional dendrimers. The kilogram-
scale synthesis is detailed in Chapter II. 
Scheme 1.2: Route used for kilogram-scale synthesis and functionalization of 
intermediates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.4 Applications Using Triazine-Based Dendrimers.   
As shown in Scheme 1.2, there are two possible intermediates, which may be 
intercepted for further manipulation.  The amine terminated dendrimer may undergo 
conjugation with an electrophilic linker while the poly(monochlorotriazine) dendrimer 
may undergo conjugation with a nucleophilic linker.  Utilizing the amine-terminated 
dendrimer as a platform for manipulation, a library of dendrimers may be synthesized 
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for a variety of applications.  Previous efforts in our lab successfully converted amine 
peripheries into carboxylate, sulfonate, phosphonate, guanidinylate and PEGylate 
peripheries.60  This work proved to successfully modulate toxicity in vitro.  
Understanding of the relative toxicity of peripheral functional groups provides a basis 
for further manipulations when implementing biologically relevant molecules.  
 Through functionalization of the amine-terminated dendrimer with succinic 
anhydride, a polycarboxylate dendrimer is obtained which may be functionalized further 
with glucosamine moieties for potential suppression of immunologic function during 
inflammation caused during disease and injury as shown when using PAMAM 
constructs.61  En route to the desired product new characterization methods using 
capillary electrophoresis were developed as a method to verify the purity obtained using 
mass spectrometry and NMR analysis.62  While the triazine-based dendrimer platforms 
appeared to be more pure and more monodisperse than their PAMAM counterparts, the 
triazine dendrimers did not seem to have any effects on the immune system.    
 Alternatively, modifying the amine-terminated dendrimer with chlorotriazine-
modified drugs has proven successful as a route toward drug delivery vehicles using 
paclitaxel.63  Attempts to attach desferrioxamine B (DFOB) to the dendrimer in a similar 
manner were also visited.  DFOB is a siderophore used in the treatment of iron overload 
due to the high affinity and high specificity for iron.  Attachment of DFOB to a 
dendrimer would enable macromolecular iron chelation.  The structure of DFOB 
(Figure 1.6) shows a linear chelate with three hydroxamic acids and one primary amine.  
Previous studies of the x-ray crystal structure provide solid-state evidence that the amine 
is outside of the coordination sphere of iron, offering a valid attachment point to the 
dendrimer.64  
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Figure 1.6: Desferrioxamine B shown in the absence of iron and in the presence of iron 
as a hexadentate chelate. 
Through exploitation of the dichlorotriazine route for attachment, the primary 
amine may react with cyanuric chloride to afford a dichlorotriazine containing DFOB.  
This molecule may then be appended from the amine-terminated dendrimer.  The similar 
pKa values between the primary amine and the three hydroxamic acids65 led to new 
strategies for the installation o DFOB onto the dendrimer.  Various routes will be 
discussed further in Chapter III. 
While drug attachment to the dendrimer through a dichlorotriazine intermediate 
has proven successful, the additional steps for drug attachment led to the development of 
an alternative method, which takes advantage of the poly(monochlorotriazine) 
containing dendrimer obtained as an intermediate in the synthesis of dendrimers.  To 
investigate this new route we chose 20-(S)-camptothecin as our drug of choice, shown in 
Figure 1.7.  The camptothecins are DNA topoisomerase-I (TOP I) inhibitors.66  When 
bound to the TOP I cleavage complex, DNA remains with a single-strand nick causing 
cell death.  Functionalization of camptothecin with a secondary amine enables for 
efficient substitution of the poly(monochlorotriazine) dendrimer, which will be 
explained in more detail in Chapter IV.  
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Figure 1.7: Camptothecin in the active lactone and inactive carboxylate forms. 
 Exploitation of a variety of synthetic routes for dendrimer synthesis has enabled 
us to obtain a dendrimer at kilogram-scale using routine laboratory equipment.  Current 
methods to derivatize this dendrimer have given mixed results.  While the success of this 
route has been largely dependent on molecule added to the dendrimer, the utility of such 
reactions will continue to be investigated by us toward the eventual goal of 
macromolecular-based therapeutics.  Current efforts to attach drugs for cancer 
therapeutics and other biologically relevant molecules will prove to fuel the future of 
research in our lab as we move from synthesis to cellular toxicity and eventually in vivo 
therapeutics.  Advances over the past ten years have proven promising to propel us into 
the next decade of applications using triazine dendrimers.  
 
 
  
17 
CHAPTER II 
 
KILOGRAM-SCALE SYNTHESIS OF A TRIAZINE-BASED DENDRIMER  
 
  
 
2.1 Introduction   
Since the development and commercialization of PAMAM dendrimers, various 
other architectures have been developed, which address issues associated with the 
application for which the architecture is intended.  Triazine-based dendrimers have had 
an impact on the field of dendrimer chemistry through the exquisite control over 
synthesis, which pushes the boundaries of design.  Early in the synthesis of triazine-
based dendrimers a third generation dendrimer was synthesized both convergently and 
divergently to afford a dendrimer with 16 terminal amines.52  The convergent synthesis 
of this dendrimer was performed in the absence of protecting group or functional group 
manipulations.  The divergent synthesis had poor yields upon addition of the monomer 
units at each generation and required multiple deprotection steps.  The poor yields may 
be attributed to the poor relative reactivity between monochlorotriazines and benzyl 
amine.  Furthermore, the reactions were carried out in organic solvents and required 
chromatography for purification. 
Shortly thereafter, complex peripheries were attained through the introduction of 
orthogonally reactive protecting groups.  The most complex dendrimer to date contains 
two hydroxyl groups, 16 BOC-protected amines, two t-butyl-diphenylsilyl (TBDPS)-
protected alcohols, two thiopyridyl disulfides and two levulinic esters for a total of five 
different functional groups and 24 total peripheral groups.67  This tailored complexity 
leads to the ability to attach specific molecules to each peripheral functional group for 
the development of multimodal theranostics containing imaging agents, drugs and 
biocompatibilizing agents.  The complexity of this construct is a synthetic feat in 
dendrimer synthesis, but suffers from the inability to produce this architecture on large 
scale at high yields without the use of column chromatography.  Since the successful 
completion of this complex triazine-based dendrimer, various other constructs were 
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developed in our lab, which come closer to development of a construct for achieving 
scalable synthesis. 
After our initial success with dendrimer synthesis, various other architectures 
were synthesized by our group, which improved on past structures.50, 51, 55, 59, 68-70  
Finally, a triazine-based dendrimer was synthesized, which utilized dichlorotriazine 
monomer units containing two BOC-protected primary amines.58  Synthesis from the 
commonly used  tris(piperazinyl) core progressed divergently through monomer addition 
and subsequent reaction with piperidine, an inert capping group.  The second-generation 
dendrimer had twelve terminal amines and was synthesized in great yield, but each 
reaction was run at a concentration of 0.1 M or less and some products required 
chromatography for purification.  While the procedure originally performed to obtain the 
dendrimer was not ideal for kilogram-scale reactions, the structure and synthetic strategy 
led to further investigation and synthetic optimization for large-scale synthesis.  
Although the synthetic route, core, monomer unit and peripheral functionality are 
among the most apparent parameters affecting synthesis, various other factors also play a 
major role in achieving dendrimer architectures at the kilogram scale.  These parameters 
include solvent, concentration and other reagents.  The majority of reactions to 
synthesize the dendrimers described above are performed in organic solvents at 0.1 M, 
which are commonplace in organic chemistry.  At the kilogram-scale, the reactions 
would generate a significant amount of organic waste at these concentrations.  To 
circumvent the issues of significant waste production, a number of efforts focused on 
optimizing reaction conditions to decrease the waste generation, to run more 
concentrated reactions and to use “green” solvents when possible.  The kilogram-scale 
synthesis of a triazine-based dendrimer is described here with attention drawn to the 
approaches used to circumvent the production of large quantities of waste.  
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2.2 Results and Discussion 
The dendrimer was synthesized through iterative reactions of monomer addition, 
capping and deprotection.  Each of these steps was performed divergently from the core 
outward to obtain a second-generation dendrimer with twelve terminal amines. 
Our initial selection of synthetic route stemmed from previous work in our lab 
and reports from other groups, which found that the divergent route is more 
advantageous for large-scale syntheses.  While the convergent synthesis produces less 
moles of product than reactant used, the divergent route has the advantage of molar 
retention by increasing the molecular weight at each generation.  The molecule central to 
this synthesis and most projects in our lab is cyanuric chloride, which undergoes 
chemoselective reactions with nucelophiles.  The core is formed by reaction of cyanuric 
chloride with three diamines to form a symmetric core with three terminal amines.  Our 
use of piperazine as the diamine affords a small molecule core with three cyclic 
secondary amines capable of reacting efficiently with mono and dichlorotriazines.  This 
reactivity has proven useful in the past when making dendrimers with piperazine at each 
generation, however, the poor yields and rigid product precludes scalability and use in 
certain applications.  Through the introduction of primary amines at the periphery of 
each generation, we are able to synthesize dendrimers with more versatile functionality.  
In an attempt to synthesize a dendrimer with primary amines on the periphery we lose 
reactivity seen with cyclic secondary amines.  To circumvent this problem we must 
introduce dichlorotriazines as the monomer unit capable of high yielding reactions with 
primary amines.  Therefore, increased yield and purity may be obtained through the use 
of a tris(piperazinyl) core and a dichlorotriazine with two primary amines.  These 
structures are shown in Figure 2.1. 
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Figure 2.1: Structure of tris(piperazinyl) core and aminodipropylamino-dichlorotriazine 
monomer.  
In the original procedure, the core molecule was synthesized through reaction of 
cyanuric chloride with excess 1-BOC-piperazine at a concentration of 0.04 M in 
tetrahydrofuran to yield 97% of the desired product.  In the large-scale synthesis, the 
concentration was only slightly higher at 0.05 M with a 96% yield.  Attempts to make 
this reaction “green” were unsuccessful as solubility was a problem in driving the 
reaction to completion.  Furthermore, the concentration that the reaction was performed 
at was optimized, but showed little improvement over the previously reported method.   
Protection of the triamine in “green” solvents also proved unsuccessful and was 
performed in tetrahydrofuran as originally reported.  The advantage was evident with the 
increased concentration of the reaction.  Originally, the reaction was carried out at 
concentration of 0.13 M in the presence of N,N-diisopropylethylamine resulting in 84% 
yield.  The large-scale reaction proceeded in the same yield at a concentration of 0.33 M.  
These reaction conditions enabled the reaction to proceed in 0.6 L instead of the 1.5 L 
used in the previous procedure.  Purification, in both cases, proceeded through 
crystallization.  Reaction of the BOC-triamine with cyanuric chloride to form the 
monomer was then performed in THF at a concentration of 0.06 M in the presence of 
DIPEA and purified by crystallization to afford the product in 87% yield.  In acetone and 
water the reaction proceeds at a concentration of 0.14 M using sodium bicarbonate as the 
base.  The product was then obtained in 96% yield after purification through 
crystallization.  The ability to synthesize the monomer unit in large scale at excellent 
yield with significantly less solvent is imperative due to the use of this monomer at each 
generation.  Synthesis of the monomer proceeded with 362 g cyanuric chloride resulting 
in 810 g of monomer.   
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The next step to form the first generation poly(monochlorotriazine) dendrimer involved 
the reaction of a single core molecule with three monomer units.  The iterative 
dendrimer synthesis to produce the second-generation dendrimer starting from the 
reaction of core and monomer is shown in Scheme 2.1.  This reaction was achieved in 
organic solvents at a concentration of 0.018 M to yield 93% of the first generation 
poly(monochlorotriazine) dendrimer.  Purification was then performed using a short 
silica gel chromatography column to by removing a majority of the impurities.  The 
eluent was then concentrated and the product precipitated.  Reaction of this product with 
piperidine, an inert capping group, at a concentration of 0.03 M yields 99% of BOC-
protected first generation dendrimer.  In acetone and water, the reaction of monomer and 
core proceeds at a concentration of 0.09 M.  Due to the excess solvent necessary to 
perform chromatographic separation and the amount of silica gel necessary, the product  
Scheme 2.1: Iterative synthesis of the second-generation dendrimer on kilogram scale. 
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obtained in the large-scale synthesis was used in the next step without further 
purification.  Slight excess in monomer unit is the only likely impurity, which is also 
capped upon reaction with piperidine.  Addition of piperidine to this dendrimer in 
acetone proceeds at a concentration of 0.025 M to afford the product in 86% yield over 
both steps after purification.  The unreacted monomer present at the beginning of this 
reaction was indeed present as the bis-piperidine capped monomer and was removed 
using a filtration rinse with acetone. 
Deprotection of the BOC-protected amines in the next step occurs in methanol at 
a concentration of 0.01 M in both cases.  Generally, a 6 M solution of hydrochloric acid 
in methanol is used to deprotect the dendrimer.  Such harsh conditions are not necessary 
to achieve the desired product, but are utilized for synthetic and purification ease.  
Previously it has been shown that the dendrimer may be deprotected using trifluoroacetic 
acid, which proceeds in comparable yields but proceeds to completion slower than when 
utilizing HCl.  The first generation dendrimer then has six terminal amines, which may 
then undergo reaction with monomer units to afford a second generation 
poly(monochlorotriazine) dendrimer with twelve BOC-protected amines and six 
monochlorotriazines. 
The second-generation dendrimer was originally achieved at a concentration of 
0.0035 M in 93% yield after purification through a short silica gel chromatography 
column and subsequent precipitation as was performed in the first generation.  The pure 
dendrimer was then reacted with piperidine at a concentration of 0.016 M to yield 99% 
of the second-generation BOC-protected dendrimer.  Alternatively, the reaction was 
performed in acetone and water at a concentration of 0.0056 M and used directly in the 
next step without further purification.  Reaction with piperidine then proceeds at a 
concentration of 0.02 M.  At this stage purification was attempted to remove the bis-
piperidine capped monomer.  The resulting solid proved to be more difficult to purify as 
the monomer was still apparent in the solid.  The inability to remove the impurity led to 
the need for a single chromatographic purification step.  Column chromatography was 
performed using ethyl acetate and hexanes as the eluting solvent for the piperidine-
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capped monomer followed by a dichloromethane solution with 30% methanol to elute 
the desired product.  A yield of 83% was determined for the collected product over both 
steps.  Finally, deprotection of the dendrimer proceeded at concentration of 0.006 in the 
original report and 0.002 in the large-scale synthesis with a 99% yield in both cases.   
2.3 Conclusions 
This synthesis was performed in five steps in 70% yield with greater than 93% 
purity for under $10/g.  While yield and purity are often parameters that measure the 
success of a synthesis, we found various other parameters that further enhance the utility 
of this construct.  The synthetic ease, purification and use of water and acetone in a 
majority of the reactions also attest to the utility and potential commercial applicability 
of this triazine-based dendrimer.  The original synthesis of this dendrimer on small scale 
was reported to the fifth generation.  The purification and characterization became 
increasingly more difficult at each iteration and required significantly more effort with 
dramatically lower yields.  Solubility and incomplete reactions also became problematic 
at the fifth generation.  At the kilogram-scale the purification and characterization would 
prove to be too cumbersome to warrant investigation up to the fifth generation and thus 
our large scale synthesis was only carried out to the second generation. 
Oftentimes, the use of specialized laboratory equipment is required for syntheses 
performed on this scale.  Such equipment includes reactor vessels with multiple valves 
and attachments for handling ease and maximum collection efficiency of the products.  
In our hands, however, we completed the synthesis using routine laboratory equipment.   
Handling 22 L round bottom flasks and 4 L separatory funnels did pose certain safety 
precautions, however, the reactions were generally performed as would be routine with a 
100 mL round bottom flask.  Crystallization as the only purification method until the 
final chromatography column was also a major advantage to this route.  The need to 
purify compounds using column chromatography is commonplace in many organic 
reactions, but oftentimes uses significant volumes of solvent to elute the product.  
Circumventing the use of chromatography decreases the amount of waste produced and 
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simplifies the collection of pure materials through filtration rather than evaporation of 
solvents.  Finally, optimizing the reactions by increasing concentrations and using 
“green” solvents also generates less waste and less environmentally hazardous waste.  
The use of green solvents in industrial reactions is of much interest now and this reaction 
moves our chemistry one step closer toward triazine-based dendrimers with commercial 
applications.  
The synthetic ease, modest yield and overall purity have propelled us to continue 
to investigate this dendrimer in a variety of applications.  The low cost also suggests a 
potential for this construct in the development of affordable medicines for the third 
world.  Our interest and success in using this platform as a drug-delivery vehicle is 
discussed later in Chapters III and IV.  
 
2.4 Experimental 
2.4.1 Materials and Methods 
All solvents and reagents were purchased from commercial suppliers and used as 
received.  Acetone (99.5%), 2-(tertbutoxycarbonyloxyimino)-2-phenylacetonitrile 
(BOC-ON), chloroform (99.8%), 3,3'-diaminodipropylamine (98%), dichloromethane 
(99.6%), N,N-diisopropylethylamine (99%), methanol (99.8%), sodium chloride, sodium 
sulfate (anhydrous) and tetrahydrofuran (99.9%, anhydrous) were purchased from 
Sigma-Aldrich. Cyanuric chloride was purchased from Alfa Aesar. N-Boc-piperazine 
was purchased from AK Scientific.  Hydrochloric acid andsodium bicarbonate were 
purchased from J. T. Baker.  Sodium hydroxide was purchased from Fisher Scientific.  
Hexanes (98.5%) were purchased from Mallinckrodt.  NMR spectra were recorded on a 
Varian Mercury 300 MHz spectrometer in CDCl3, or DMSO-d6.  All mass spectral 
analyses were carried out by the Laboratory for Biological Mass Spectrometry at Texas 
A&M University.  HPLC analysis was performed using a Waters Delta 600 system and a 
Waters UV detector at 280 nm.  Either a Zorbax C-8 column (4.6 x 50 mm) was used at 
30 °C with a flow rate of 0.7 mL/min or a Halo C18 column (4.6 x 50 mm, 2.7 µm) was 
used at 50 °C with a flow rate of 1.5 mL/min.  The mobile phase in both cases was a 
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95/5 (0.5% HClO4 in water/acetonitrile) with a gradient to 5/95 (0.5% HClO4 in 
water/acetonitrile) over 3 minutes, and an isocratic hold for 4 min followed by a gradient 
of 95/5 (0.5% HClO4 in water/acetonitrile) over 7 min. 
2.4.2 Synthesis of 1,3,5-[Tris-piperazine]-triazine   
A 1-L, three-necked, roundbottomed flask, fitted with a magnetic stirrer, 
condenser, nitrogen inlet, and 250 mL addition funnel was charged with 1,3,5-[N-(tert-
butoxycarbonyl)-piperazine]-triazine (27.9 g, 44.1 mmol, 1.00 equiv) and 286 mL of 
methanol.  The solution was left to stir at 0 °C for 30 min.  A solution of 153 mL (0.918 
mol, 21 equiv) of 6 N hydrochloric acid was then added over 70 min. keeping the 
temperature at ~ 1 °C and the resulting light yellow slurry was left to stir at 0 °C for 2 h.  
The reaction slurry then warmed to ambient temperature over 3 h and slowly heated to 
an internal temperature of 40 °C for 12 h (the slurry became homogeneous at 27 °C).  
Off-gassing was observed as the temperature increased.  The volatile organic 
components were removed using a rotary evaporator 34–40 °C until only ca. 100 mL of 
water remained.  The resulting aqueous solution was cooled to 0 °C and made alkaline 
(pH = 14) by addition of 237 mL (657 mmol, 15 equiv.) of a 10% NaOH solution.  The 
resulting alkaline solution was then extracted with chloroform (3 x 250 mL), and the 
organic phases were combined and dried over sodium sulfate.  The solvent was filtered 
and evaporated at 34 °C to afford the product as a white solid (14.1 g, 96 %), mp 200–
208 °C. 
The product has the following characteristics: TLC Rf = 0.0 (silica gel 60 F254, 
EMD Chemicals, Inc. in 10% methanol:dichloromethane); IR (neat) cm-1: 3278, 2846, 
1523, 1433, 1242, 1007, 806, 728; 1H NMR (400 MHz, CDCl3) δ: 1.62 (s, 3 H), 2.81 (t, 
12 H, J = 5.0), 3.68 (t, 12 H, J = 5.0); 13C NMR (100 MHz, CDCl3) δ: 44.3, 46.0, 165.2; 
MS (CI) m/z 334.4 Anal. Calcd. for C15H27N9: C, 54.03; H, 8.16; N, 37.81. Found: C, 
53.72; H, 8.32; N, 37.48. 
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2.4.3 Synthesis of 3,3’-Di-(tert-butoxycarbonyl)-aminodipropylamine   
A 1 L, three-necked, round-bottomed flask equipped with a magnetic stirrer, a 
500-mL addition funnel, a temperature probe and a static nitrogen inlet was charged with 
3,3'-diaminodipropylamine (28.2 mL, 0.20 mol, 1.0 equiv), 300 mL of tetrahydrofuran, 
and N,N-diisopropylethylamine (100 mL, 0.57 mol, 2.8 equiv.).  A separate 500-mL 
Erlenmeyer flask was charged with 2-(tert-butoxycarbonyloxyimino)-2-
phenylacetonitrile (BOC-ON) (100 g, 0.41 mol, 2.0 equiv.) and 300 mL of 
tetrahydrofuran.  The resulting solutions were separately stirred at 0 °C for 30 min.  The 
BOC-ON solution was then transferred to the addition funnel and added dropwise to the 
solution of 3,3'-diaminodipropylamine over a 90-100 min period. After addition was 
complete, the solution was left to stir at 0 °C for 3 h, warmed to ambient temperature, 
and left to stir for an additional 20 h. The solvent was removed using a rotary evaporator 
at 39 °C and the residue was dissolved in 400 mL of dichloromethane. The organic 
solution was washed with 10% NaOH (3 x 200 mL), a saturated, aqueous solution of 
sodium chloride (1 x 300 mL), and dried over sodium sulfate.  Following filtration, the 
solvent was removed using a rotary evaporator at 32–39°C to afford the product as an 
oily material which was then precipitated as an off-white solid by addition of hexane 
(500 mL) and traces of MeOH (3 mL).  After standing in the freezer for 24 h, the solids 
were filtered, washed with hexane, and dried under vacuum overnight to provide the 
product as an off-white solid (54.2–55.9 g, 82–84 %), mp 68.1–70.0 °C. 
The product has the following spectral characteristics: TLC Rf = 0.0 (silica gel 
60 F254, EMD Chemicals, Inc. in 5:95 methanol:dichloromethane); IR (neat) cm-1: 3342, 
2975, 2931, 1686, 1518, 1365, 1273, 1250, 1168; 1H NMR (400 MHz, CDCl3) δ: 1.41 
(s, 18 H), 1.60–1.66 (m, 4 H), 2.63 (t, 4 H, J = 6.6), 3.15–3.20 (br, 4 H), 5.2 (br, 2 H); 
13C NMR (100 MHz, CDCl3) δ: 28.4(s), 29.7 (s), 38.9 (s), 47.4 (s), 78.9 (s), 156.1 (s); 
MS (CI), m/z 332.2 (M+H). Anal. Calcd. for C16H33N3O4: C, 57.98; H, 10.04; N, 12.68. 
Found: C, 57.86; H, 9.84; N, 12.51. 
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2.4.4 Synthesis of 2-[3,3’-Di-(tert-Butoxycarbonyl)-aminodipropylamine]-4,6- 
dichloro-1,3,5-triazine   
A 3-L, three-necked, round-bottomed flask equipped with a mechanical stirrer, 
static nitrogen inlet and 1-L addition funnel was charged with cyanuric chloride (30.5 g, 
0.165 mol, 1.00 equiv) and 300 mL of acetone.  The resulting solution was left to stir at 
0 ºC for 1 h.  A cooled solution of 3,3’-di-(tert-butoxycarbonyl)-aminodipropylamine 
(54.9 g, 0.166 mol, 1.01 equivalent) in acetone (686 mL) was then added dropwise to the 
cyanuric chloride solution over a period of 3 h (the internal temperature remained at or 
below 2 ºC during this addition).  A white suspension formed during the course of 
addition.  Sodium bicarbonate (13.9 g, 0.166 mol, 1.00 equiv) in water (195 mL) was 
then added dropwise over a period of 1 h.  A yellow mixture was obtained after complete 
addition.  The resulting solution was left to stir at 0 ºC for 3 h, which resulted in the 
formation of a white suspension.  The mixture was allowed to warm to ambient 
temperature and stirred for an additional 15 h.  The reaction mixture was concentrated 
without filtration (to approximately 200 mL) on a rotary evaporator at 31–40 °C.  The 
resulting aqueous suspension was filtered.  The solids were dissolved in 600 mL of 
dichloromethane and washed with water (3 x 250 mL), and a saturated, aqueous solution 
of sodium chloride (300 mL). The organic layer was dried with sodium sulfate, filtered, 
and the solvent was concentrated using a rotary evaporator at 40 °C.  The resulting solids 
were dried under vacuum to provide the product as an off-white solid (76.5 g, 0.160 mol, 
96 %), mp 122.4-125.7 °C. 
The product has the following characteristics: TLC Rf = 0.3 (silica gel 60 F254, 
EMD Chemicals, Inc. in 5% methanol:dichloromethane); IR (neat) cm-1: 3349, 2976, 
1691, 1573, 1475, 1233, 1160, 847, 733; 1H NMR (400 MHz, CDCl3) δ: 1.41 (s, 18 H), 
1.77 (tt, apparent quintet, 4 H, J = 6.6), 3.07-3.12 (br/quartet-depending on sample 
concentration, 4 H), 3.60 (t, 4 H, J = 7.1), 5.05 (br, 2H); 13C NMR (100 MHz, CDCl3) δ: 
27.7 (s), 28.3 (s), 37.3 (s), 44.9 (s), 79.3 (s), 156.0 (s), 164.7 (s), 170.1 (s); MS (CI): m/z 
479, 379. Anal. Calcd. for C19H32Cl2N6O4: C, 47.60; H, 6.73; N, 17.54; Cl, 14.79.  
Found: C, 47.87; H, 6.82; N, 17.48; Cl, 14.47. 
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2.4.5 Synthesis of 1,3,5-[Tris-N-(tert-butoxycarbonyl)-piperazine]-triazine 
A 2 L, three-necked, round-bottomed flask equipped with a magnetic stirrer, 
reflux condenser, temperature probe, glass stopper and static nitrogen inlet was charged 
with cyanuric chloride (10.0 g, 54.2 mmol, 1.00 equiv) and tetrahydrofuran (1 L).  N-
(tert-Butoxycarbonyl)-piperazine (34.0g, 183 mmol, 3.38 equiv) was added in ~10 g 
portions over 17 min (during the addition, the temperature rose from 20 to 28 °C; an 
ambient temperature water bath was used to moderate the exotherm).  White solids 
formed in the reaction mixture during the addition of the piperazine.  N,N-
Diisopropylethylamine (96.2 mL, 552 mmol, 10.2 equiv) was then added, and the 
reaction mixture stirred at ambient temperature for 1 h, then heated to an internal 
temperature of 66 °C for 20 h at which point the reaction was judged to be complete by 
HPLC.  Upon cooling to ambient temperature, a white precipitate forms.  The solvent is 
removed using a rotary evaporator at 31 °C.  The white residue was taken up in 
dichloromethane (300 mL) and washed with water (2 x 150 mL), 10% NaHSO4 (2 x 150 
mL) and a saturated, aqueous solution of sodium chloride (2 x 100 mL).  The organic 
layer was dried over anhydrous sodium sulfate, filtered, and the solvent was removed 
using a rotary evaporator at 35–41 °C.  The resulting white solids are granulated in 
EtOAc (35 mL, ca. 1 mL/g) to yield a white crystalline material (31.0–32.0 g, 90–93 %), 
mp 223.4–226.1 °C. 
The product has the following characteristics: TLC, Rf 0.35 (silica gel 60 F254, 
EMD Chemicals, Inc. in 5% methanol:dichloromethane); IR (neat) cm-1: 1679, 1535, 
1419, 1227, 998, 725; 1H NMR (400 MHz, CDCl3) δ: 1.46 (s, 27 H), 3.42 (m, 12 H), 
3.72 (m, 12 H); 13C NMR (100 MHz, CDCl3) δ: 28.4, 43.0, 79.9, 154.8, 165.2; MS (CI) 
m/z 634.3; Anal. Calcd. for C30H51N9O6: C, 56.85; H, 8.11; N, 19.89. Found: C, 56.69; 
H, 8.26; N, 19.82. 
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2.4.6 Synthesis of G1-[N(CH2CH2CH2NHBoc)2]3-Cl3   
In a 4-L, 4-necked, jacketed reaction vessel equipped with a 250-mL addition 
funnel, temperature probe, static N2 and mechanical stirrer, 2-[3,3’-di-(tert-
butoxycarbonyl)-aminodipropylamine]-4,6-dichloro-1,3,5-triazine (73.0 g, 0.152 mol, 
3.5 equiv.) was dissolved in acetone (1 L) and cooled to 0 °C.  Separately, a chilled 
solution of 1,3,5-[tris-piperazine]-triazine (14.5 g, 43.5 mmol, 1.0 equiv) in H2O (500 
mL) was prepared and treated with a solution of sodium carbonate (46.1 g, 0.435 mol, 10 
equiv.) in 250 mL of H2O.  This solution was left to stir at 0 °C for 30 min.  The 
resulting aqueous solution was added in a dropwise fashion to the acetone solution at 0 
°C over a period of 2 h.  The white suspension obtained after complete addition was left 
to stir at 0 °C for 2.5 h before warming gradually to 21 °C, and then stirred for an 
additional 20 h.  The white solid was collected by filtration on a 15 cm-diameter 
Büchner funnel.  The reaction vessel was rinsed with 500 mL water, which was 
subsequently used to wash the filter cake.  The wet solids were transferred back to the 
rinsed reaction vessel and dissolved in CH2Cl2 (1.5 L), washed with water (3 x 200 mL), 
a saturated, aqueous solution of sodium chloride (1 x 1.5 L), and then dried with 230 g 
of sodium sulfate.  Following filtration, the solvent was removed using a rotary 
evaporator at 30 °C and dried under vacuum to yield an off-white crude material (76.1 
g).  This material was used in the next step without further purification. 
A small amount of the product was purified for spectral characterization using 
column chromatography on silica gel eluting with 10% EtOAc:CH2Cl2 to give the 
unreacted starting material C3N3[N(CH2CH2CH2NHBoc)2]Cl2 as a white solid followed 
by elution with (50:50) EtOAc:CH2Cl2 to give the product as a white solid. 
The product has the following characteristics: TLC Rf = 0.28 (Silica Gel 60 F254, 
EMD Chemicals, Inc., 20:1 CH2Cl2:CH3OH); IR (KBr pellet) cm-1: 3375, 2976, 2931, 
1713, 1571, 1539, 1493, 1437, 1390, 1367, 1248, 1167, 1081, 1041, 999, 983, 880, 801, 
620, 465; 1H NMR (400 MHz, CDCl3) δ: 1.44 (s, 54 H, C(CH3)3), 1.75 (m, 12 H, 
NCH2CH2), 3.08 (m, 12 H, CH2NHBoc), 3.57 (m, 12 H, Boc-NCH2), 3.82 (m, 24 H, 
CH2, piperazine), 4.84 (br, 3 H, NH), 5.58 (br, 3 H, NH); 13C NMR (100 MHz, CDCl3) 
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δ: 28.0 (s, NCH2CH2), 28.1 (s, NCH2CH2), 28.6 (s, C(CH3)3), 28.7 (s, C(CH3)3), 37.0 (s, 
CH2NHBoc), 38.0 (s, CH2NHBoc), 42.9 (s, CH2), 43.1 (s, CH2), 43.6 (s, CH2, 
piperazine), 44.1 (s, CH2), 79.1 (s, C(CH3)3), 79.5 (s, C(CH3)3), 156.1 (s, C(O)), 156.4 
(s, C(O)), 164.6 (s, C3N3), 165.2 (s, C3N3), 165.4 (s, C3N3), 169.6 (s, C3N3); HRMS 
(Thermo LTQ FT Ultra): Calcd. for (M+H): 1660.8746. Found: 1660.87555. Anal. 
Calcd. for C72H120Cl3N27O12: C, 52.02; H, 7.28; N, 22.75; Cl, 6.40. Found: C, 52.14; H, 
7.30; N, 22.63; Cl, 6.48. 
2.4.7 Synthesis of G1-[N(CH2CH2CH2NHBoc)2]3-piperidine3  
In a 4-L, 4-necked, jacketed reaction vessel equipped with a temperature probe, 
static N2 inlet, glass stopper and mechanical stirrer, G1-[N(CH2CH2CH2NHBoc)2]3-Cl3 
(74.8 g, 43.5 mmol, 1.0 equiv) was suspended in acetone (3 L) and left to stir at 0 °C for 
1 h.  Piperidine (79.3 mL, 68.4 g, 803 mmol, 18.5 equiv) was added in a single portion 
and the mixture stirred at 0 °C for 4 h.  A white suspension formed after 30 min.  The 
mixture warmed to 21 °C and stirred for an additional 20 h, at which time the reaction 
was judged to be complete by HPLC. The resulting suspension was filtered, washed with 
acetone (100 mL), and air-dried overnight to afford 97.3 g of a white solid.  The white 
solid was dissolved in CH2Cl2 (1000 mL), transferred to a 2-L separatory funnel and 
washed with a 5% HCl solution (4 x 300 mL), 5% NaOH solution (1 x 300 mL), and a 
saturated, aqueous solution of sodium chloride (1 x 300 mL).  The organic phase was 
dried over sodium sulfate (108 g) and the solvent was removed on a rotary evaporator at 
30 °C to afford an off-white solid that was dried in a vacuum oven for 96 h to provide 
67.4 g of the title product (86% yield over two steps). 
 The product has the following characteristics: TLC Rf = 0.36 (Silica Gel 60 F254, 
EMD Chemicals, Inc., 20:1 CH2Cl2:CH3OH); IR (KBr pellet) cm-1: 2975, 2931, 2853, 
1717, 1530, 1487, 1434, 1366, 1293, 1249, 1173, 997; 1H NMR (400 MHz, CDCl3) δ: 
1.42 (s, 54 H, C(CH3)3), 1.56 (br, 12 H, C5H10N, β-H), 1.62 (br, 6 H, C5H10N, γ-H), 1.71 
(br, 12 H, NCH2CH2), 3.06 (br, 12 H, CH2NHBoc), 3.59 (br, 12 H, CH2, Boc-NCH2), 
3.73 (br, 12 H, C5H10N, α-H), 3.80 (br, 24 H, CH2, piperazine), 5.26 (br, 6 H, NH); 13C 
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NMR (100 MHz, CDCl3) δ: 25.1 (C5H10N, γ-C), 26.0 (C5H10N, β-C), 27.8 (s, 
NCH2CH2), 28.7 (s, C(CH3)3), 37.4 (s, CH2NHBoc), 41.9 (C5H10N, α-C), 43.2 (s, Boc-
NCH2), 43.4 (s, Boc-NCH2), 44.4 (s, CH2, piperazine), 79.1 (s, C(CH3)3), 156.2 (s, 
C(O)), 165.1 (s, C3N3), 165.5 (s, C3N3), 166.1 (s, C3N3); HRMS (Thermo LTQ FT Ultra) 
[M+H] calcd. for C87H150N30O12: 1808.2120. Found: 1808.20932. Anal. Calcd. for 
C87H150N30O12: C, 57.78; H, 8.36; N, 23.24. Found: C, 57.45; H, 8.10; N, 22.90. 
2.4.8 Synthesis of G1-[N(CH2CH2CH2NH2)2]3   
Prior to starting the reaction, methanol and concentrated HCl were cooled to 0 °C 
for 3 h.  In a 22 L three neck roundbottomed flask fitted with a mechanical stirrer was 
dissolved G1-[N(CH2CH2CH2NHBOC)2]3 (315 g, 0.17 mol) in CH3OH (9 L) and the 
mixture was allowed to stir at 0 °C for 30 min.  Concentrated HCl (12 N, 4.5 L) was 
added in 500 mL portions over a period of 2.5 h with a 15 min interval between each 
addition.  The temperature slightly rose to 5 °C after addition.  After complete addition, 
the resulting yellow solution was left to stir at 0 °C for 15 h and at 25 °C for 24 h.  The 
volatile components were concentrated in vacuo until only about 800 mL of water 
remained.  After cooling to 0 °C, the residue was made basic (pH = 14) with 1.5 L of a 5 
M NaOH (aq.) solution.  The resulting white suspension was filtered and attempt to dry 
this compound under vacuum and with low heating was unsuccessful. The solid was 
partially dissolved in CHCl3 (4 L). The organic phase was separated by filtration.  The 
remaining solid was dissolved in H2O (3 L), and the resulting milky solution was 
extracted with CHCl3 (1 L) using a 1 L size liquid-liquid extractor. The extraction was 
stopped when the aqueous solution turned clear (4-5 h).  Fresh CHCl3 was used after two 
successive extraction (500 mL each).  The organic fractions were combined, dried with 
Na2SO4, and filtered, and the solvent was removed under reduced pressure. The desired 
material was isolated as a white solid by precipitation from the oily solution using 
hexane and upon standing for 48 h in the freezer (205 g, >99%). 1H NMR (300 MHz, 
CDCl3) δ: 3.74 (br, 24H), 3.66 (br, 12H), 3.58 (br t, 3JH-H = 7 Hz, 12H), 2.63 (br, 12H), 
1.68 (br m, 12H), 1.57 (br, 6H), 1.49 (br, 12H), 1.38 (br, 12H). 13C NMR (75.5 MHz, 
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CDCl3) δ: 165.5, 165.2, 164.8, 44.0, 43.0, 42.4, 39.1, 39.0, 31.3, 25.7, 24.9. MS 
(MALDI): calcd. 1206.8904 (M)+, found 1207.9496 (M + H)+. Anal. Calcd. For 
C57H102N30•2H2O: C, 55.03; H, 8.52; N, 33.79. Found: C, 55.13; H, 8.16; N, 33.39. 
2.4.9 Synthesis of G2-[N(CH2CH2CH2NHBOC)2]6-Cl6   
A 22 L, three-neck roundbottomed flask equipped with a mechanical stirrer was 
charged with 130 g (0.11 mol) of G1-[N(CH2CH2CH2NH2)2]3 and 5 L of H2O.  A 
solution of Na2CO3 (205 g, 1.94 mol) in 1.5 L of H2O was added, and the resulting slurry 
solution was stirred at 25 °C for 1 h.  A solution of dichlorotriazine monomer(310 g, 
0.65 mol) in acetone (13 L) was added, and the reaction mixture was stirred at 25 °C for 
36 h.  The reaction was monitored by MALDI-TOF MS and TLC (silica gel, 5% CH3-
OH/CH2Cl2, Rf = 0.2) and deemed to be complete as a result a yellow gummy 
precipitated at the bottom of the flask during this time.  The solvent was removed on 
rotary evaporator (13 L), and the resulting aqueous suspension was dissolved in CH2Cl2 
(4 L).  The aqueous layer was removed, and the organic phase was washed with H2O (3 
x 500 mL) and brine (3 x 500 mL) and dried with Na2SO4.  Following filtration, the 
solvent was removed on rotary evaporator to afford a white crude material (420 g, 99%).  
Both TLC and MALDI-TOF MS analysis of this material showed the presence of the 
desired product along a small amount of unreacted monomer.  This material was suitable 
for use without further purification; however, a small amount was purified for spectral 
characterization using column chromatography on silica gel (40:1 CH2Cl2/CH3OH; Rf = 
0.19 using 20:1 CH2Cl2/CH3OH as developing solvent) to afford the product as a white 
solid. The excess/unreacted monomer may also be recovered from this purification (Rf  = 
0.50 using 20:1 CH2Cl2/CH3OH as the developing solvent).  1H NMR (300 MHz, 
CDCl3) δ: 6.60-4.80 (br, 18H), 3.80 (br, 24H), 3.72 (br, 12H), 3.56 (br, 36H), 3.36 (br, 
12H), 3.05 (br, 24H), 1.83 (br, 12H), 1.70 (br, 30H), 1.60 (br, 12H), 1.42 (s, 54H), 1.39 
(s, 54H). 13C NMR (75.5MHz, CDCl3) δ: 169.2, 168.4, 165.4, 165.1, 164.9, 164.6, 
156.0, 155.7, 78.9, 78.6, 44.0, 37.6, 36.6, 28.2, 27.7, 25.6, 24.8. MS (MALDI): calcd. 
3860.1476 (M+), found 3860.5223. Anal. Calcd. for C171H288Cl6N66O24: C, 53.14; H, 
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7.51; N, 23.92; Cl, 5.50.  Found: C, 53.31; H, 7.52; N, 23.79; Cl, 5.41. 
2.4.10 Synthesis of G2-[N(CH2CH2CH2NHBOC)2]6-piperidine6   
In a 22 L three-neck roundbottomed flask fitted with a mechanical stirrer, G2-
[N(CH2CH2CH2NHBOC)2]6Cl6 (1240 g, 0.32 mol) in acetone (16 L) was allowed to stir 
at 25 °C for 1 h. To the resulting solution was added piperidine (470 mL, 5.59 mol), and 
the mixture was allowed to stir at 25 °C for 48 h at which point the reaction was judged 
complete by MALDI-TOF MS and TLC (silica gel, Rf ) 0.49 using 5% 
CH3OH/CH2Cl2). The resulting suspension was filtered, washed with acetone (2 L), 
and dried to afford 238 g of a lightweight white material. Analysis (NMR, MS, and 
TLC) of this material showed the presence of the pyridinum chloride salt and none of the 
desired product, and it was therefore discarded. The filtrate was evaporated to dryness 
under reduced pressure to yield a yellowish white solid.  TLC analysis (SiO2, 5% 
MeOH-CH2Cl2) of the crude product showed two spots under UV lamp, one with an Rf 
value of 0.34 that corresponds to the desired product and the second with an Rf value of 
0.48 and corresponds to piperidine capped monomer. Furthermore, a ninhydrin stain 
showed the presence of a third spot at the baseline which corresponds to the excess 
piperidine. The crude product was dissolved in CHCl3 (8 L) and was washed with 5% 
aqueous HCl solution (3 x 2 L), 5% aqueous NaOH solution (3 x 2 L), and then brine (3 
x 1 L). TLC monitoring confirmed the disappearance of the excess piperidine. The 
organic phase was dried with Na2-SO4, and the solvent was removed in vacuo to afford a 
crude product which was passed through a chromatography column, eluting with 
EtOAc-hexane (1:1) to isolate the impurities, followed by a 30% CH3OH-CH2Cl2 elution 
to isolate the product.  The appropriate fractions were collected, and the solvent was 
removed under reduced pressure.  The resulting yellowish white solid was dried under 
vaccum for 3 days.  Yield: 1.105 kg, 83%. 1H NMR (300 MHz, CDCl3) δ: 6.71-4.85 (br, 
18H), 3.80 (br, 24H), 3.70 (br, 36H), 3.55 (br, 36H), 3.36 (br, 12H), 3.04 (br, 24H), 1.83 
(br, 12H), 1.68 (br, 24H), 1.58 (br, 18H), 1.53 (br, 36H), 1.38 (s, 108H). 13C NMR (75.5 
MHz, CDCl3) δ: 165.7, 165.3, 164.9, 164.5, 156.0, 78.8, 44.0, 43.0, 41.9, 37.0, 28.4, 
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27.6, 25.7, 24.8. MS (MALDI): calcd 4154.8224 (M+), found 4155.2448 (M + H+).  
Anal. Calcd. for C201H348N72O24: C, 58.07; H, 8.44; N, 24.26. Found: C, 57.91; H, 8.33; 
N, 24.48. The piperidine capped monomer sideproduct was recovered during purification 
(92 g).  1H NMR (300 MHz, CDCl3) δ: 5.35 (br, 2H), 3.69 (t, 3JH-H = 5 Hz, 8H), 3.56 (t, 
3JH-H = 6 Hz, 4H), 3.02 (t, 3JH-H = 6 Hz, 2H), 3.00 (t, 3JH-H = 6 Hz, 2H), 1.66 (m, 4H), 
1.60 (br, 4H), 1.54 (br, 8H), 1.40 (s, 18H).  13C NMR (75.5 MHz, CDCl3) δ: 166.0, 
164.9, 156.0, 78.8, 44.1, 41.0, 36.8, 28.4, 27.4, 25.7, 24.9. MS (ESI): calcd. 576.4112 
(M+), found 577.3884 (M + H+).  Anal. Calcd. for C29H52N8O4: C, 59.41; H, 8.96; N, 
19.12. Found: C, 59.20; H, 8.96; N, 19.69. 
2.4.11 Synthesis of G2-[N(CH2CH2CH2NH2)2]6  
Concentrated aqueous HCl (50 mL) was added to a solution of G2-
[N(CH2CH2CH2NHBOC)2]6 (5.0 g, 0.32 mmol) in CH3OH (100 mL), and the clear 
solution was stirred at 25 °C for 24 h. The volatile components were concentrated in 
vacuo until only ca. 40 mL of water remained.  The residue was made basic (pH = 14) 
with 85 mL of 10% NaOH (aq) solution, and the resulting milky suspension was 
extracted with CHCl3 (1 L) using a liquid-liquid extractor until the alkaline aqueous 
solution became clear. The organic phase was dried over Na2SO4, and then the solvent 
was removed in vacuo to afford the product as a white solid.  Yield: 3.51 g, >99%. 1H 
NMR (300 MHz, CDCl3 with trace CD3OD) δ: 5.22 (br, 6H), 3.68 (br, 24H), 3.60 (br, 
12H), 3.52 (br, 36H), 3.45 (br, 24H), 3.19 (br, 12H), 2.48 (br, 24H), 1.69 (br, 12H), 1.57 
(br, 24H), 1.48 (br, 18H), 1.39 (br, 36H).  13C NMR (75.5 MHz, CDCl3 with trace 
CD3OD) δ: 165.8, 165.4, 165.2, 165.1, 165.0, 164.6, 164.3, 43.8, 42.8, 41.7, 38.1, 37.3, 
30.3, 27.7, 25.5, 24.6. MS (MALDI): calcd 2954.1932 (M+); found 2955.0237 (M + 
H+). Anal. Calcd. for C141H252N72•1.5CHCl3: C, 54.54; H, 8.08; N, 32.15. Found: C, 
54.80; H, 8.08; N, 32.48. 
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CHAPTER III 
THE USE OF TRIAZINE-BASED DENDRIMERS AS MACROMOLECULAR 
AGENTS FOR IRON-OVERLOAD THERAPY 
 
3.1  Introduction 
3.1.1  Iron-Overload 
Iron is a necessary metal for normal cellular metabolism and respiration, 
however, excess levels of iron are cytotoxic and fatal if left untreated.71  Iron absorption 
from the gut into the body and subsequent transport to organs involves a complex 
pathway of proteins not yet fully understood.72  The uptake of iron is known to be highly 
regulated through various factors including iron deficiency and hypoxia, both of which 
increase iron absorption.71  Alternatively, iron-overload and inflammation decrease 
absorption.71  Intestinal epithelial cells absorb about 1-2 mg of iron per day through the 
divalent metal transporter 1 (DMT1), which equates to about 10% of daily dietary 
uptake.71  The body has no active mechanism for the release of iron.  In cases of iron-
overload, desquamation, menstruation and other blood loss maintains iron homeostasis.73  
The body is therefore considered a closed system, recycling the iron which is taken up 
and storing excess iron for emergency situations such as major blood loss and anemic 
conditions.71  The acute and chronic uptake and storage of excess iron in the body 
represents a group of hereditary and acquired conditions referred to as iron-overload 
which cause severe problems in normal organ function.74  Therapeutic methods to 
sequester iron must be employed to actively remove iron from the body in states of 
excess.  Such techniques have been shown to be effective through improved kidney 
filtration in the urine and biliary drainage from hepatocytes into the fecal matter of 
chelated iron complexes.74  Iron-overload is the most common, chronic metal toxicity 
condition worldwide with the highest morbidity and mortality rate.75  
Iron overload has been found to be both a genetic disorder present in recessive 
and dominant forms and as an acquired disorder from dietary and transfusional uptake of 
iron.71  The disorder was first described in diabetic patients with skin discolorations in 
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1865,76 however, the connection with iron was not made until 1890.77  Hereditary 
hemochromatosis was later described by Sheldon in 1935,78 but a great deal was still 
unknown about the disease leaving it quite difficult to treat.  Since that time, various 
genetic mutations have been observed and used to classify the disorder into five different 
types of hereditary hemochromatosis, however, discrepancies arise throughout the 
literature as some forms of the disorder are not understood.71, 74, 79  
Type 1 hereditary hemochromatosis is the most common form of iron overload 
as it affects between 1:200 and 1:500 people in the world equaling about 1 million 
American cases.80  The HFE gene responsible for Type 1 hemochromatosis was first 
cloned in 199681 and mutations of the gene were found to prevent dimerization of the 
encoded protein through missense mutations of cysteine for tyrosine at position 282.82  
The cysteine is believed to participate in protein-protein complex formation with the 
transferrin receptor, however, it is unclear how this disrupts the regulation of iron.83  
Other proteins and signaling pathways have been identified, including hepcidin,84 
tranferritin receptor 285 and hemojuvelin.86  In states of excess iron, hepcidin has been 
found to decrease iron absorption from the gut and prevent loss of iron from 
macrophages.84, 87  Hepcidin is upregulated by the proteins mentioned here among many 
others, which are expressed in the presence of excess iron.  The role of each protein is 
still unclear, but dramatic effects are observed when mutations of these proteins are 
investigated.71 
Secondary iron overload, or acquired iron overload is most often caused by 
multiple blood transfusions throughout one’s lifetime due to other disorders.  
Thalassemia, for example, is a chronic disease marked by anemia due to insufficient 
production of one globulin chain that forms hemoglobin.88, 89  This reduced production 
of one globin chain causes abnormal hemoglobin formation resulting in poor iron 
complexation and eventually anemia.  Thalassemia remains one of the leading causes of 
iron overload due to the blood transfusion therapy required to treat patients suffering 
from this disorder.90  Blood transfusions tend to cause elevated levels of free iron due to 
iron present in the blood from lysed blood cells, making iron-overload a major indirect 
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side effect of thalassemia.91  There are an estimated 100 million asymptomatic 
heterozygous thalassemia carriers worldwide with more than three quarters of the 
thalassemia population living in the Middle East, South East Asia and the 
Mediterranean.92 
Excess iron remains a problem for several reasons, but Fenton-like chemistry is 
the major concern of iron toxicity within the body, leading to oxidation of cellular 
organelles and cellular membranes.93-95  The oxidative potential requires that iron be 
complexed in proteins such as transferrin, hemoglobin and ferritin.  Transferrin consists 
of two iron binding regions and functions in iron transport throughout the blood.  It is 
estimated that only about 1% of total body iron is located in transferrin, which is about 
25-40% saturated at any given time.96  The majority of iron is stored in cellular domains 
within the liver and heart among other organs.96  With such small amounts of iron 
present in blood proteins and the variance of iron within the proteins, it is quite difficult 
to assess the actual levels of iron within the body.  Furthermore, it is unclear what levels 
of iron constitute iron overload and what levels of iron are actually toxic.97 
Free radical reactions associated with iron overload have been shown to cause 
lipid peroxidation of cells and cellular organelles causing membrane breakdown and 
cellular death and eventual tissue and organ dysfunction.98-100  The heart, liver and 
endocrine system are the most common organs affected by iron-overload due to the 
propensity for iron to be taken up in these organs.90  Excess iron stored in the heart tissue 
may cause congestive heart failure,101 pulmonary hypertension102 and myocarditis.103  In 
the liver, portal fibrosis and cirrhosis remain major life-threatening side-effects of iron 
overload, which are shown to accelerate with viral infection and alcohol use.88, 104-107 
The endocrine system is commonly affected by iron through hormonal 
deficiencies, which affect growth and reproduction while also affecting insulin 
production due to pancreatic iron uptake causing diabetes mellitus.108-110  Treatment of 
patients with chelation therapy has shown dramatic results in reducing the side effects 
related with iron overload and a great decrease in the mortality rate when iron-overload 
is detected in a timely manner.90  While heart and liver disease are the most common 
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causes of death in iron overload patients, the levels of blood flow necessary in the brain 
also causes damage to brain tissue.  A great deal of research is currently focused on 
disorders such as Alzheimer’s disease,111, 112 Parkinson’s disease,113, 114 multiple 
sclerosis115 and central pontine myelinolysis,116 and their association with iron among 
other metals.117-119  It has been found that transferrin deficient mice continue to receive 
high levels of iron in the brain ruling out the possibility that transferrin is the only 
vehicle which takes iron to the brain, however, intracellular trafficking is inhibited and 
produces iron pools causing subsequent tissue oxidation.120-122 
Despite the high occurrence, many physicians inaccurately consider 
haemochromatosis to be a rare disease due to poor diagnosis.123  Measurement of body 
iron levels has proven to be one of the major obstacles in diagnosis of iron-overload due 
to the inadequacies of detection.  Indirect methods of measuring iron levels include 
measurement of serum ferritin concentrations,124 serum transferrin saturation,125 
desferrioxamine-induced urinary iron excretion,126 imaging of iron,127 and evaluation of 
organ function.128  Heart biopsy,129 liver biopsy and superconducting susceptometry with 
a Superconducting QUantum Interference Device (SQUID)130 are the three methods of 
direct iron measurement.  Direct tests are more ideal in the correlation of actual body 
iron levels; however, these tests are often invasive, painful and expensive.  More 
commonly, indirect tests are performed, which tend to lack specificity and sensitivity 
with low correlation to actual iron levels.  Indirect tests, however, are generally non-
invasive and are inexpensive, but questionable results require further examination 
through direct methods and eventual therapy when a positive detection is achieved.  
3.1.2 Desferrioxamine B as an Iron Sequestration Agent 
Several iron specific chelation therapies have been proposed, however, the Food 
and Drug Administration has approved only three agents for preclinical or clinical use, 
to date, for iron overload therapy.  Deferriprone (Ferriprox) as an investigational new 
drug, deferasirox (Exjade)131 and desferrioxamine B (Desferal) are shown in Figure 3.1.  
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Desferrioxamine B (DFOB) is the most widespread therapy used, however, a significant 
amount of literature is available on the others.92, 132-138 
 
Figure 3.1: DFOB, Exjade and Ferriprox with corresponding iron complexes. 
Desferrioxamine B (DFOB) is a siderophore produced by Actinomycetes (Streptomyces 
pilosus) and was first isolated and characterized in 1960.139  Siderophores are microbial 
metabolites produced and released in oxic conditions to mobilize and allow for cellular 
trafficking of insoluble ferric ions for cellular function.140  Many siderophores are known 
to chelate various metals, however, the hydroxamate functionality present in the 
ferrioxamine family of siderophores creates a highly specific iron chelate for cellular 
trafficking.141 The ferrioxamines are a specific class of hydroxamate-based siderophores, 
which exist in linear and cyclic conformations.142  DFOB is a linear ferrioxamine with a 
wide range of affinities for a variety of metals.  Metal chelation for various applications 
with DFOB has been studied using Zr(IV);143 V(IV) and V(V);144 Cr(III);145 Mn(III);146 
Fe(II) and Co(III);147 Sr(II), Cu(II), Ni(II), Zn(II) and Mo(VI);147-149 Ga(III), In(III) and 
Al(III);150-153 Sn(II), Bi(III) and Hg(II);154 Pb(II) and Eu(III);155 Th(IV) and Pu(IV).156  
The metal binding affinity of DFOB for a variety of metals is shown in Figure 3.2, 
which is determined through correlation of the log K values of the DFOB with the log K 
values for hydroxide ions.65  The linear relationship offers insight into the correlation 
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between acidity of the metal ion while the low y-intercept indicates the level of 
preorganization.157  Ferric ions are hard and quite acidic requiring negatively charged, 
strongly basic oxygen donors for chelation as is present in the hydroxamic acid moieties 
of DFOB.158  While the basicity favors more acidic metals, the low level of 
preorganization leads to slow metallation and demetallation kinetics providing a highly 
selective iron chelate.157  
 
 
Figure 3.2:  Correlation of log KMLH values for DFOB against KM(OH) values for various 
metal ions.65  
 
The three hydroxamic acids moieties present in DFOB form a hexadentate 
octahedral complex around iron (III) at physiological pH.64  This complex creates a cis 
(facial) configuration forming two trigonal octahedral faces with the hydroxyls and 
carbonyl oxygens, of the three hydroxamates.64  Furthermore, the solid state crystal 
structure shows that the primary amine present in the molecule does not contribute to the 
stability of the complex, but forms a dimer through electrostatic interaction with a 
perchlorate ion.64  It has been proposed that the amine is used as a solubilizing group and 
as a recognition unit for cellular trafficking,64 and thus it has also been the target of 
DFOB functionalization.159-165  
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While DFOB has an affinity for many metals, the high affinity for iron(III) 
presents the use of this siderophore as a therapy for iron-overload.166-169  Initial studies 
with DFOB found that the drug was not orally available due to low lipophilicity, mainly 
due to the charged primary amine at physiological conditions, leading to only 15% 
bioavailability when orally administered.167  Recommendations for the delivery of 
DFOB were shortly thereafter developed for the treatment of acute iron poising 
involving placement of 5-10g of DFOB in the stomach after gastric lavage, followed by 
i.v. administration of DFOB with regular urine monitoring.170  The approval of the drug 
by the US Food and Drug Administration in 1968 opened the door to much more testing 
and development of an administration regimen.  The effectiveness of 24 h i.v. 
infusions,171, 172  24 h subcutaneous administration173, 174 and 12 h subcutaneous 
infusions175 were reported.  Currently, however, DFOB is most commonly administered 
through subcutaneous infusion over 6 or 7 hours, seven days a week as a person sleeps.95  
While the chronic regimen required has improved over the past few decades, the 
treatment of iron-overload using this method causes non-compliance with many patients 
due to high cost ($10,000-$30,000 annually), discomfort and minor side effects in a 
small number of patients.138 
The side effects of Desferrioxamine B are rare, but include ocular and auditory 
abnormalities,176-185 sensorimotor neurotoxicity,186 changes in renal function,187, 188 and 
pulmonary toxicity189, 190 as well as evidence of failure to grow due to cartilaginous 
dysplasia in the spine and long bones.191-196  Toxic side effects are generally observed 
over prolonged periods and during high-dose usage, as DFOB chelates metals and 
undergoes reduction to form oxidants197 or as DFOB-Fe infiltrates the healthy cells and 
acts in the same manner.198 Thus, the short half-life of DFOB poses problems due to the 
high rate of glomerular filtration by the kidneys199 and plasma metabolism200, 201 
requiring high dose injections causing many of the undesired side-effects over time.  
Investigation of the major pathway for metabolism found that the plasma was 
responsible for the majority of inactivation of DFOB as compared to metabolism in the 
pancreas, small intestine, brain, liver, muscle, and spleen in various animals.200  
  
42 
Remarkably, human and dog plasma had significantly lower rates of DFOB metabolism 
as compared to rat, rabbit, guinea-pig, cat, bovine and pig, while mice had the fastest 
rate of metabolism.200  Studies have proven that the major metabolites found in the urine 
involve conversion of the primary amine into a series of oxygenated species, which have 
decreased binding affinity.202, 203  This data is in direct contradiction to the assertion that 
the primary amine does not contribute to the stability of the complex.  With such high 
levels of renal filtration of both the free chelate and the iron complex, spectroscopic 
studies of patient urine after therapy may be performed to determine if free iron is 
present in the blood.204  While DFOB is generally considered a chelate for non-
transferrin bound iron in the blood, it has also been found to mobilize iron from ferritin 
storage within cells,205 but poor lipophilicity of the chelate prevents cellular penetration.  
It is believed that DFOB must become internalized into the cell through endocytosis to 
have a direct effect on intracellular iron stores.  This has been shown through in vitro 
cell studies that have undetectable decreases in intracellular iron stores treated with 
DFOB except in the case of Kupffer cells in the liver, which readily undergo endocytosis 
to easily allow DFOB to enter the cell.206  
Although the majority of DFOB applications involve iron-overload, the chelation 
ability of DFOB may also be exploited in a variety of avenues including MR imaging, 
207, 208 PET imaging,143 antibacterials and antibiotics,209 superoxide dismutase mimics,146 
hypoxia-mimetic agent210, 211 and cancer therapy.147, 151, 153, 165, 212 
 
3.1.3 The Development of Alternative Small Molecule Iron Chelates  
Much research has now focused on the development of lipophilic iron chelates, 
which are then orally available and may easily traverse cell membranes and chelate non-
transferrin bound iron stores within the cell.  Two drugs, for example, which achieve 
these goals, are deferasirox and deferiprone.  However, these orally active therapies 
suffer from side effects including nausea, abdominal discomfort, and high potential for 
renal failure among others.138  Annual cost for deferasirox (Exjade®) has been estimated 
at $20,000-$60,000, thus, preventing widespread usage in the US as well as many 
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developing countries.138  While delivery remains the major drawback of DFOB, the 
minimal side effects and low cost allows DFOB to remain as the desired chelation agent 
of choice.    
Alternatively, small molecule bis-(hydroxylamino) triazine-based chelates have 
been developed by Melman and coworkers, which show high Fe(III) binding specificity 
in competition with other metals.213, 214  Such structures have been synthesized in high 
yield and also show high binding affinity for Vanadium oxide for magnetic resonance 
imaging215 and titanium for cancer therapy.216-218  While limited studies are available on 
these chelates, the potential for further explotation of this ligand system which take 
advantage of synthetic ease and scalability are warranted.  
3.1.4 Macromolecular Iron Chelation Agents 
From the promising clinical data obtained with DFOB and the less than ideal 
pharmacokinetics of the therapy, the desire to find chelation therapies able to remain in 
the blood for significant lengths of time has attracted a great deal of focus.  Prolonged 
blood plasma half-lives of macromolecular agents has shown great success due to the 
decreased glomerular filtration and hepatic cellular trafficking allowing for longer 
plasma circulation times.24, 33, 37  Using increased size as an aid in developing chelating 
agents, DFOB was attached to dextran or hydroxyethyl-starch (HES) biocompatible 
polymers through reductive amination after oxidation of the polysaccharide.159, 160, 219  
DFOB loading on the polysaccharides varied according to the amount of periodate used 
in the oxidation of the starch and the amount of DFOB used in reductive amination, 
however, dextran had 20-30% incorporation by weight while HES had only 10-20% 
incorporation by weight.159 Attempts to calculate the relative toxicity of the polymer-
DFOB conjugates compared to DFOB alone and polymer-DFOB-Fe compared to 
DFOB-Fe failed due to the amount of dose necessary leading to lethal hypervolemic and 
hyperoncotic effects.  The LD50 values for DFOB and DFOB-Fe through i.v. 
administration are 0.4 and 1.4 µmol/g, respectively, which are much below the range of 
the polymer conjugates.219  During in vivo experiments with mice in which acute iron 
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poisoning was induced with iron sulfate injection or oral administration immediately 
followed by therapy, 100% survival was achieved with the conjugate compared to 22% 
for DFOB alone and 30% for polymer alone.219  Efficacy of injection 1 hour after 
administration of iron resulted in 77% survival as compared to 0% survival in the other 
cases.219  Furthermore, the long retention times in the vasculature of a mouse increased 
from 5.5 minutes for free DFOB to 67 minutes for the dextran conjugate and 84 minutes 
for the HES conjugate.159  Iron excretion in the urine also proved to be comparable and 
better than DFOB alone,159 leading the eventual pre-clinical studies in human subjects.160  
Plasma half-life of between 22 and 32 hours were reported for the HES-DFOB 
conjugates depending on the dosage, which ranged from 0.3 mL/kg to 9 mL/kg.160  
Generally 35-55% of initial dose of drug was recovered in the urine 48 hour along with 
up to 7 mg iron as compared to 0.06 mg in control patients.160  The major drawback of 
this therapy was the 14,000 to 200,000 Da molecular weight range associated with the 
conjugates.160  Development of monodisperse macromolecular iron sequestration agents 
such as chelate decorated dendrimers is of interest. 
The first report of metal sequestration using dendrimer constructs appeared in 
1999 for the sequestration of Cu(II) in unmodified PAMAM dendrimers.220  This work 
opened the door to directed iron sequestration using salicylate-, catecholate- and 
hydroxypyridinonate-functionalized dendrimers for the sequestration of iron.221-224  The 
advantage of using such monodisperse agents allows for more concrete characterization 
as compared to the dextran and starch therapeutics.  The development of new dendrimer-
chelate constructs remains a topic of interest.  Our investigations toward the attachment 
of DFOB to triazine-based dendrimers are described. 
 
3.2 Results and Discussion 
3.2.1 Selective Reaction of the Primary Amine of DFOB   
When devising a strategy to install DFOB on the dendrimer, both the 
nucleophilic and electrophilic linkage routes must be considered.  The crystal structure 
of DFOB-Fe has shown that the primary amine is not involved in complexation, which 
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would suggest that selective functionalization of the amine would be the route of choice 
for attachment to the dendrimer.  The amine alone is a nucleophile, however, primary 
amines such as this generally do not react easily with poly(monochlorotriazine) 
containing dendrimers.  Therefore, we aimed to pursue the electrophilic route, where 
DFOB is reacted with cyanuric chloride to produce the dichlorotriazine.  Initial attempts 
to obtain this molecule proved problematic due to the similar pKa values, and thus 
similar reactivities, between the primary amine and each of the hydroxamic acids.65  The 
similar reactivity of each nucleophile in DFOB led to the formation of oligomers and 
polymers as determined by MALDI-TOF mass spectrometry.  The poor selective 
reactivity toward cyanuric chloride led us to attempt various other amine selective 
chemistries, including reductive amination and acetate protection of the hydroxamic 
acids in the presence of 18-crown-6 as a transient amine protecting group.  Each attempt 
at selective functionalization proved futile in our hands and a new method was needed.  
To circumvent the nucleophilicity of the hydroxamic acids, iron was also utilized 
as a protecting group, which could be removed later through a number of potential 
routes.  The lewis acidity of iron and the catalytic effect on chlorotriazine substitution is 
believed to catalyze the reaction to generate a mixture of mono- and di-substituted 
triazines.  Understanding the reactivity of triazines and the results from this reaction, a 
dichlorotriazine containing propargylamine was then reacted with DFOB-Fe(III) to 
afford the desired monochlorotriazine as shown in Scheme 3.1.  When reacted with the 
primary amine terminated second-generation dendrimer, however, complete reaction 
was unattainable.  This result, although undesirable, was understood due to the poor 
nucleophilicity of primary amines, poor electrophilicity of monochlorotriazines, the 
steric hindrance and poor solubility of the product.  
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Scheme 3.1: Synthesis of the monochlorotriazine containing Fe-DFOB unable to add to 
the dendrimer due to poor reactivity, solubility and sterics.  
 
An alternative route for selective functionalization was then attempted using 
azide transfer chemistry.  The Alper-Wong azide transfer reaction converts primary 
amines into azides through the use of triflic azide in the presence of a copper catalyst.225  
This reaction has been shown to proceed efficiently in the presence of a variety of 
functional groups and in high yield.  Desferrioxamine B proved to be an ideal molecule 
for this reaction as the conversion of the primary amine to an azide proceeded in 62% 
yield.  The obtained azide may then undergo the Huisgen-Sharpless “click” reaction.226  
Click reaction of the DFOB-azide with alkyne terminated dendrimers to afford the 
dendrimer-DFOB construct through a triazole linkage as shown in Scheme 3.2, proved 
problematic.  While this reaction is robust and proceeds in a variety of conditions with a 
wide range of substrates, DFOB however, is unsuccessful as only a portion of DFOB-
azide has been attached to the dendrimer.  This incomplete reaction may be due to 
chelation of copper by desferrioxamine preventing catalysis to occur, however issues 
with solubility are more likely the ultimate limitation of this chemistry as amine 
functionalized DFOB has been shown to inhibit solubility.163  Incomplete reactions may 
occur due to the hydrogen bond interactions present in the final product, which form 
insoluble aggregates.  While poor solubility may be the culprit, methods to solubilize 
lipophilic drugs covalently and non-covalently linked to dendrimers have been addressed 
in the past.  However, due to the extremely explosive triflyl azide intermediate used in 
the azide transfer reaction, this method has been abandoned.   
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Scheme 3.2: An unsuccessful click reaction with desferrioxamine B-azide and an 
alkyne-containing dendrimer. 
 
3.2.2 Increasing the Nucleophilicity of the Primary Amine 
Another method to attach DFOB to the dendrimer is to increase the 
nucleophilicity of the primary amine with cyclic secondary amines, which will enable 
reaction with a poly(monochlorotriazine) dendrimer.  Increasing the nucleophilicity of 
the primary amine through reaction with isonipecotic acid allows for reaction with 
chlorotriazines as the third substitution.  This has been achieved through a one-pot 
reaction of DFOB with the NHS-ester of Fmoc-protected isonipecotic acid and 
deprotection to produce Inp-DFOB.  Poor characterization data by mass spectrometry 
has led us to characterize the compounds using NMR alone.  Purification is carried out 
through filtration with water to remove DBU, followed by toluene to remove 9-
methylene fluorene produced in the deprotection.  The secondary amine is then capable 
of reacting as the third substituent on the triazine ring using the 
poly(monochlorotriazine) dendrimer obtained in the kilogram-scale synthesis as shown 
in Scheme 3.3.  During this reaction an insoluble mass forms, which is insoluble in all 
solvents for further characterization.  Attempts to characterize the solid by NMR, mass 
spectrometry and infrared spectroscopy resulted in insufficient data to quantify the 
extent of the reaction or evidence of a reaction occurring at all.  It is likely that the poor 
mass spectral data obtained with DFOB alone is likely compounded when multiple 
chelates are attached to the dendrimer.  NMR was also unsuccessful at providing 
adequate data for a reaction taking place.  The poor solubility of DFOB and the sterics 
  
48 
involved are likely to hinder reaction with the dendrimer.  Various attempts to achieve 
the desired product using this construct resulted in solid masses, which were 
uncharacterizable.  Other constructs also provided similar results with characterization 
showing greater potential than in the kilogram-scale dendrimer, but complete 
substitution was never achieved. 
Scheme 3.3: Synthesis of Inp-DFOB and subsequent unsuccessful reaction with the 
poly(monochloro triazine) dendrimer. 
 
 To overcome issues of solubility, PEG-mono-methylether was reacted in one pot 
with cyanuric chloride to form the first substitution followed by reaction with the 
dendrimer.  Purification of the poly(monochlorotriazine) dendrimer was performed using 
ultrafiltration through regenerated cellulose membranes. The need for higher molecular 
weight PEG chains also led to a loss of monodispersity of the starting material inhibiting 
characterization of the product.  This route was abandoned and further attempts to 
functionalize the dendrimer with DFOB was determined to be unwarranted.  
3.3. Conclusions 
Iron-overload is a serious condition, which is believed to affect a significant 
number of people around the world.  The symptoms of this disease are oftentimes 
characterized as old age.  Proper diagnosis requires invasive testing, which is still 
inaccurate due to the patient variability and the inability to accurately classify the limits 
of iron toxicity.  However, when testing concludes that patients are suffering from the 
disease, therapy must be implemented to diminish the side effects.  Current therapies 
include deferrioxamine B, deferiprone and deferasirox.  
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Desferrioxamine B is considered the gold standard in the treatment of iron-
overload.  While it has been used widely in patients with both hereditary 
hemochromatosis and secondary hemochromatosis, the poor bioavailabilty and 
inconvenient route of administration prevents the drug from achieving its full potential.  
New small molecule chelates such as deferiprone and deferasirox have improved 
bioavailability, but possess other issues such as toxicity and high cost.  With poor drug 
pharmacokinetics and toxicity with the currently approved therapies, the utilization of 
polymer technologies provide additional benefits in treating this disease.  From 
carbohydrate polymers containing DFOB to dendrimers with synthetic chelates, the field 
of polymer based iron chelation is burgeoning and continues to improve therapy. 
In our hands, attachment of DFOB to a dendrimer has proven unsuccessful due to 
similar reactivities of the amine and hydroxamic acids.  Furthermore, the solubility of 
the chelate and the inability to characterize insoluble products obtained through reaction 
with DFOB-Inp and the poly(monochlorotriazine) dendrimers were largely unsuccessful.  
While partial reaction was eventually achieved in one situation using a dendrimer 
containing propargylamine as one substituent on a poly(monochlorotriazine) dendrimer 
the ability to achieve monodisperse constructs for chelation therapy was never met. 
Attachment of DFOB to polydisperse polymers has been achieved in the past, but the 
utilizion of triazine-based dendrimers has proven to be problematic thus far and does not 
warrant further investigation with our current dendrimer system.  Alternatively, the use 
of synthetic triazine-based small molecule chelates have shown great promise in iron 
chelation and shows greater promise toward inexpensive polymer therapeutics for the 
treatment of iron-overload. 
3.4 Experimental 
3.4.1 Materials and Instrumentation   
All reagents were procured from Sigma-Aldrich (St. Louis, MO) and used as 
received without further purification.  Fmoc-protected isonipecotic acid was purchased 
from NovaBiochem (San Diego, CA) and used without further purification.  NMR 
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spectra were recorded on a Varian Mercury 300 MHz spectrometer in CDCl3, or DMSO-
d6.  All mass spectral analyses were carried out by the Laboratory for Biological Mass 
Spectrometry at Texas A&M University.  
3.4.2 Synthesis of Desferrixoamine B-Isonipecotic Amide   
A round bottom flask containing 959.9 mg of desferrioxamine B mesylate (1.46 
mmol) dissolved in 20 mL THF stirred on ice for 30 minutes.  Then 655.0 mg Fmoc-Inp-
NHS (1.46 mmol) was added and the reaction stirred warming to room temperature for 
12 h.  The reaction became cloudy white during this time.  Then, 0.2 mL of 1,8-
diazabicyclo[5.4.0]undec-7-ene (DBU) (1.34 mmol) was added to the solution and the 
solution immediately cleared and a precipitate formed.  The solution stirred for 6 h and 
was concentrated in vacuo.  The residue was then mixed with water to form a precipitate, 
which was filtered and collected.  The resulting solid was then mixed with toluene to 
form 422 mg (0.63 mmol, 43%) of the off-white solid product collected by filtration.  1H 
NMR (300MHz, CDCl3): 1.21 (br m, 6H), 1.37 (br m, 6H), 1.49 (br m, 6H), 1.62 (br m, 
4H), 1.89 (t, 1H), 1.96 (s, 3H), 2.26 (t, 3H), 2.30 (s, 1H), 2.45 (s, 1H), 2.50 (t, 2H), 2.52-
2.67 (m, 8H), 2.90 (br m, 2H), 2.99 (q, 4H), 3.23 (t, 6H), 3.44 (t, 6H), 3.52 (br d, 1H), 
7.81 (br s, 3H).  13C NMR (75MHz, CDCl3): 22.2, 25.8, 28.4, 29.6, 36.8, 43.6, 48.3, 
52.8, 154.2, 161.9.   
3.4.3 Synthesis of Desferrioxamine B-Containing Dendrimer   
A round bottomed flask containing 12 mg of G2-[N(CH2CH2CH2NHBOC)2]6 
(0.004 mmol) stirred in 1 mL THF as 50 mg DFOB-Inp (0.074 mmol) was added to the 
solution.  Then, 0.2 mL DIPEA was added and the solution continued to stir for 7d.  A 
solid was obtained, which could not be characterized.  The solution was concentrated 
and showed starting material by NMR and MS.   
 
 
  
51 
CHAPTER IV 
TRIAZINE-BASED DENDRIMERS CONTAINING CAMPTOTHECIN AS 
DRUG DELIVERY VEHICLES FOR CANCER THERAPY* 
 
4.1 Introduction 
The camptothecins are cytotoxic, quinoline alkaloids characterized by a planar 
pentacyclic ring system.227, 228  Isolated using an anticancer activity screen by Wall and 
Wani in 1966 from the bark of Camptotheca acuminata,227  20-(S)-camptothecin suffers 
from many limitions including poor solubility, rapid clearance, high systemic toxicity 
and/or poor selectivity toward cancer cells.39  A year after the discovery of 
camptothecin, Wall and Wani discovered paclitaxel, another anticancer drug, which also 
showed great promise.229  While both drugs showed powerful anticancer activity,230 
camptothecin’s poor solubility and unpredictable adverse drug interactions favored the 
development of paclitaxel as a broad spectrum chemotherapeutic.231  
The camptothecins gained much interest in the late 1980’s when the molecular 
target was identified: DNA topoisomerase I (TOP I) is believed to be the single point of 
biological activity.232-237  Crystal structures later confirmed the binding pocket for 
camptothecin as well as for a series of other compounds.238-240  TOP I is an essential 
enzyme that relaxes supercoiled DNA prior to transcription through the formation of 
single strand breaks and religation.  Upon irreversible binding to TOP I, camptothecin 
prevents religation and causes apoptosis.  Pommier has reviewed the literature focusing 
on the genetic basis of TOP I inhibition.66 
Various structure activity relationships have shown that while the A-D rings of 
camptothecin are necessary to maintain activity, modifications of these rings attenuate 
efficacy.241  The E-ring lactone, however, is necessary for activity due to the binding site  
____________ 
* Reproduced by permission of The Royal Society of Chemistry: Venditto, V.J.; Allred, 
K.; Allred, C.; Simanek, E.E. Chem. Commun. 2009, 5541-5542. 
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found in TOP I.242  Upon removal of the lactone or hydrolysis to the carboxylate, all 
activity is lost.  Camptothecin in the active lactone form and inactive carboxylate form 
are shown in Scheme 4.1.  The equilibrium between the closed, active lactone and the 
open, inactive carboxylate form is further influenced by both the affinity of the 
carboxylate for human serum albumin and the local pH in vivo.243  Originally, 
camptothecin was delivered as the sodium salt of the carboxylate to help overcome 
solubility issues, however, the poor efficacy created a need for new alternatives.244  Two 
camptothecin derivatives, irinotecan and topotecan, were eventually approved for 
clinical use along with 10-hydroxycamptothecin, another naturally occurring derivative.  
Currently, the camptothecins ― notably topotecan,245-251 irinotecan,252-257 9-
aminocamptothecin,258, 259 9-nitrocamptothecin260, 261 and belotecan262 ― are commonly 
used as a late-stage therapy either alone or in combination therapies.  
Scheme 4.1: Camptothecin in the lactone form and open carboxylate form. 
 
Even given the hydrolytic sensitivity, the drug remains highly active as an 
anticancer agent.  When delivered in an intralipid formulation through i.m. 
administration, camptothecin showed nearly 100% growth inhibition and regression in 
colon, lung, breast, stomach, ovary and malignant melanoma xenografts.263   
Pharmacokinetic studies of camptothecin in the lactone and carboxylate forms 
were performed in rats to better understand the focus of future work.264  In various 
buffers at 37 °C the carboxylate was shown to be the predominant form.  In PBS at pH 
7.2, 7.4 and 8.0, the half-life of the lactone was 33 min, 22 min and 5.3 min, 
respectively. Furthermore, equilibrium was achieved between both forms 90 minutes 
after injection of either 1 mg/kg lactone or carboxylate in rats.  The carboxylate was 
  
53 
cleared at a much faster rate through the urine and bile as compared to the lactone form.  
Clearance was also shown to be pH dependent, suggesting that decreasing pH of the 
urine may reduce bladder toxicity caused by the carboxylate form.265  Additional studies 
in dogs, monkeys, rats and mice showed toxic effects, including emesis, diarrhea, 
dehydration, coma and death.  Intravenous administration of 80 mg/kg or five doses of 
0.625 mg/kg/day in dogs showed cumulative toxicity that was entirely reversible in 
survivors.266  In human subjects, unpredictable toxicity associated with camptothecin 
halted clinical trials and opened the door for new antitumor agents.267-271  The 
preparation and assessment of derivatives through classical structure activity 
relationships led to increased efficacy and better understanding of such activity. 
Structure activity relationships (SAR) have been carried out, which have led to 
the development of new camptothecins with potent antitumor activity.237, 241, 244, 272-278  
Many efforts focused on stabilizing the lactone without compromising cytotoxicity.  To 
summarize the SAR studies, the A and B rings are the most tolerant to modification with 
substitutions at positions 7, 9, 10 and 11 improving or retaining activity.  Altering the C 
and D rings or substituting positions 12 and 14, however, inactivates the molecules.  
Interestingly, von Hoff has provided evidence that substitutions which increase hydrogen 
bonding at the 7-position improve binding to TOP I, thus increasing activity over 
camptothecin.279  The E-ring, where binding to TOP I occurs, may undergo only minor 
modifications without dramatic negative effects. Additionally, modification of the C20 
hydroxyl group through alkylation or acylation has been shown to stabilize the lactone 
by creating a prodrug form, which is the favored method to link camptothecin covalently 
to polymer constructs.  
Quinoline ring modifications of camptothecin are the most common.  These 
derivatives show increased solubility, lactone stability and antitumor activity.  
Derivatives include the FDA approved drugs, irinotecan280 and topotecan278 among 
many others.  Quinoline modified camptothecins, which have been investigated in vivo 
are shown in Figure 4.1.  Many quinoline modifications have aimed to improve 
solubility through introduction of protonable amines.274, 278, 280-284  While other  
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Figure 4.1: Quinoline modified camptothecins. 
derivatives, including the siletecans,285, 286 and chimmetican287 have been synthesized to 
improve lipophilicity for improved blood brain barrier trafficking.  Additional small 
molecule derivatives, which have not been investigated in vivo include Low’s peptide 
folate conjugate,288 Chen’s 20-O-linked esters289 and Battaglia’s polyamine 
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conjugates.290 Some modified lactone derivatives have been investigated in vivo 
including, the E-ring enlarged homocamptothecins characterized by a seven-membered 
beta-hydroxy lactone.291, 292  While the homocamptothecins have shown improved 
lactone stability, irreversible inactivation of the drug through lactone hydrolysis is also 
observed. 
Esterification or alkylation of the 20-hydroxyl group has also shown improved 
lactone stability in small molecules293 and has become the favored method for covalent 
attachment in macromolecular drug delivery vehicles.  A hypothesis proposed in 1992 
implicates the hydroxyl group as a mediator of lactone hydrolysis by activation of water 
through a hydrogen bond interaction.294 
The covalent conjugation of camptothecins to macromolecular architectures has 
shown great potential for improving pharmacokinetics and increasing tumor efficacy.  
Various covalent constructs have been tested in vivo including micelles,295 linear 
polymers296-302 and branched polymers.303, 304  Most commonly, camptothecin is attached 
to the polymer through an ester bond with the 20-hydroxyl moiety.  This linkage not 
only conveys solubility through conjugation with a water-soluble polymer, but also 
improves lactone stability.  Some linkages are chosen as specific substrates for 
enzymatic cleavage, while others are used due to their pH sensitivity, but may also 
undergo hydrolysis.  Covalent constructs offer advantages and disadvantages over non-
covalent assemblies.  Of the advantages, the opportunity to execute structure-activity 
studies in a very narrowly defined composition space is attractive.  Disadvantages 
include, in addition to constituting a new drug entity, the burden of characterization. The 
characterization of covalent macromolecular constructs is oftentimes not trivial, and 
enthusiasm for biological results need to be tempered with the critical evaluation of the 
claims on composition.  Noncovalent constructs have also been investigated in vivo 
including micelles,305, 306 liposomes,307-312 nanoparticles313-315 and hydrogels.316, 317  Various 
other covalent318-327 and noncovalent68, 328, 329  architectures have also been developed but 
still untested in vivo.  Our approach to macromolecular covalent constructs for the 
delivery of camptothecin are discussed along with preliminary cytotoxicity data. 
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4.2 Results and Discussion 
Upon completion of the kilogram-scale synthesis of a second generation 
dendrimer,5 with attributes of a “universal” drug delivery vehicle we aimed to 
functionalize with camptothecin.  Here, we describe the interception of the 
poly(monochlorotriazine) dendrimer with a camptothecin linked nucleophile.  Our 
synthesis of the ester derivative of CPT (Scheme 4.2) utilizes 1-BOC-isonipecotic acid 
under standard coupling conditions to afforded 3 in 97% yield after methanol 
crystallization. Subsequent deprotection with trifluoroacetic acid gives the TFA salt of 4 
in 82% after precipitation with methanol.  Installation of the constrained secondary 
amine is a critical design element.  These amines have been shown to be highly reactive 
towards monochlorotriazines.20  
Scheme 4.2: Installation of BOC-Inp on 20-(S)-camptothecin through a hydrolysable 
ester linkage. 
 
 
 
 
 
  
 
Scheme 4.3 shows the route for elaboration to the final products.  Reaction of 4 with 
1 was accomplished in N,N-dimethylformamide in the presence of N,N-
diisopropylethylamine at 50 oC for 12 days to yield dendrimer 5. While higher 
temperatures may accelerate this reaction; accelerated hydrolysis of the camptothecin 
ester led us to pursue this more conservative approach. Reaction progress could be 
followed with MALDI-TOF mass spectrometry with the desired species, 5, appearing 
initially at day 4. While the spectra produced depend on matrix and ionization 
conditions, the reaction was continued until only lines corresponding to product, loss 
of BOC, and loss of a single CPT were observed.  Purification was accomplished 
using Sephadex LH-20 size exclusion chromatography.  While  1H and 13C NMR 
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corroborates the presence of six CPT groups on the dendrimer, NMR cannot be used 
to unambiguously quantify purities of these species due to the broad signals 
ineherent in these dendrimers. 
  Dendrimer 5 was deprotected using trifluoroacetic acid to afford 6 in nearly 
quantitative yield. PEGylation of the deprotected dendrimer was carried out using 
2000 Da NHS-mPEG leading to dendrimer 7. While both targets are water soluble, 7 
was purified by ultrafiltration using a YM3 regenerated cellulose membrane in an 
Amicon stirred cell. 
Scheme 4.3: Elaboration of the poly(monochlorotriazine) dendrimer to the amine 
and PEGylated targets.  
 
 
 
 
 
 
 
 
  Cytotoxicity is measured using an assay that employs (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide, or yellow MTT.   The MTT assay quantitates 
the amount of living cells through the activity of mitochondria.  In living cells, 
mitochondrial reductase converts the yellow tetrazole of MTT to a purple colored 
formazan.  Therefore, the color of the media will not change when all the cells die 
from the cytotoxic agent investigated.  Decreasing the dose from toxic to non-toxic 
generates a dose response curve.  Evaluation of the dose-response curve at a 
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concentration where 50% of the cells die generates the IC50 value or the value where 
50% of the cells are inhibited from proper function.  Lower IC50 values therfore 
correspond to compounds with increased toxicity. 
  The cytotoxicity data for our compounds in comparison to the free drug is 
summarized in Table 4.1 and is reported with respect to CPT concentration.  
Treatment of MCF7 and HT-29 cells provided dose dependent response curves for all 
analytes.  The IC50 value for CPT was 0.2 µM regardless of cell line, while the IC50 
value for irinotecan varied with line, 52 µM or 33 µM. Targets 6 and 7 showed 
intermediate values suggesting both an enhanced solubility of the construct over free 
CPT and similar behaviors of cationic and PEGylated vehicles.  A drug-free 
dendrimer bearing piperidine groups instead of isonipecotic esters showed no toxicity 
up to 10 µM (60 µM in CPT equivalents) in MCF-7 cells, but an IC50 value of 2 µM 
in HT-29 cells. At this time it is unclear why there is a pronounced difference in 
toxicity between cell lines. Similar cell specific cytotoxicity has been observed using 
cyclic peptides.21  Given the success of these constructs in vitro, further optimization 
of the synthetic strategy could offer routes to scales of material required for 
additional inquiry. 
Table 4.1: IC50 values of free drug and dendrimer-drug conjugates determined by 
MTT assay.a 
Cells CPT Irinotecan G2-NH2b G2-CPTd G2-CPT-PEG2000d 
MCF-7 0.2 52 14 9 13 
HT-29 0.2 33 >60c 8 3 
a IC50 values are reported in µM over three experiments in triplicate unless otherwise stated. 
b Value is reported in terms of six potential CPT as compared to G2-CPT. 
c No toxicity was observed up to the maximum dendrimer concentration of 10 µM determined by 9 experiments 
in triplicate. 
d Values are reported in terms of six CPT present in each molecule.  
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4.3 Conclusions  
  Triazine-based dendrimers have shown promise as drug delivery vehicles, 
however further investigation must be completed to determine the full potential of 
such constructs.  Through covalent attachment of camptothecin to the dendrimer 
through a hydrolysable linkage, we are able to improve the water solubility over the 
parent drug.  The camptothecin containing PEGylated and cationic dendrimers both 
show improved water solubility over camptothecin alone and increased toxicity over 
the water soluble derivative, irinotecan.  Our next step toward utilizing this triazine-
based dendrimer containing camptothecin involves the efficacy of this construct in 
animals with human tumor xenografts.   
  As we move forward toward in vivo therapeutics, interpatient variability will 
likely play a significant role in success.  Interpatient variability with both 
macromolecular constructs and free drug continues to hamper the widespread use of 
camptothecins.  Some variability in pharmacokinetics has been shown to occur due to 
a mutation in ABCG2 transporter proteins when using diflomotecan.330  This protein 
is believed to be responsible for natural detoxification and has been found to be 
overexpressed in the placenta, liver and intestine.  Allele mutations have shown 
dramatically increased plasma AUC values for molecule substrates, which include 9-
AC,331 SN-38332 and topotecan.333  Although allele variants may provide insight into 
potential pharmacokinetic outcomes, it is likely that other physiological differences 
in tumors such as vascularization and expression of other proteins, may also cause 
variability.  To overcome such challenges, our constructs are poised for codelivery of 
camptotehcin and DNA or RNA for transfection.  Delivery of genetic information 
encoded for TOPI or ABCG2 protein expression will likely improve efficacy.  
Transfection enhanced toxicity with irinotecan has been observed through 
introduction of carboxylesterase enzymes,334 which convert irinotecan to the active 
metabolized form in the cell rather than at the liver prior to tumor accumulation.  
Investigation with camptothecins using both transfection assisted therapy and 
macromolecular therapy is warranted. 
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4.4 Experimental 
4.4.1 Materials and Instrumentation   
All reagents were procured from Sigma-Aldrich (St. Louis, MO) and used as 
received without further purification.  NHS-mPEG was purchased from NOF American 
Corporation.  Amicon filters (YM-3: MWCO 3kDa) were purchased from Millipore.  
Size exclusion chromatography (SEC) was carried out using a Waters Delta 600 system 
and a Waters 2414 refractive index detector.  A Suprema 10 micron GPC analytical 
column (1000 Å, 8 x 300mm) was used with 0.1 M NaNO3 as the eluent and a flow rate 
of 1 mL/min.  NMR spectra were recorded on a Varian Mercury 300 MHz spectrometer 
in CDCl3, or DMSO-d6.  All mass spectral analyses were carried out by the Laboratory 
for Biological Mass Spectrometry at Texas A&M University.  MCF-7 (human breast 
cancer) cells were purchased from ATCC.  Cells were maintained in phenol red free 
DMEM (Sigma) containing 10% fetal bovine serum (FBS) at 37°C in a 5% CO2 
atmosphere.  HT-29 (human colon cancer) cells were purchased from ATCC.  Cells were 
maintained in phenol red free DMEM F-12 (Sigma) containing 10 % FBS and 1% 1M 
HEPES.   
4.4.2 Synthesis of BOC-Inp-CPT (3)  
A solution of 1.40 g BOC-Inp (6.11 mmol) in 50 mL dichloromethane stirred as 
3.55 g 1-ethyl-3-(3’-dimethylaminopropyl) carbodiimide (18.5 mmol) and 0.78 g N,N-
dimethylaminopyridine (6.38 mmol)were added.  After stirring for 30 minutes, 1.50 g 
camptothecin (4.31 mmol) was added and stirring continued for 18 h.  The solution was 
concentrated in vacuo and the residue was precipitated with methanol to yield a yellow 
solid.  Yield: 2.34 g, (4.18 mmol), 97%.  ESI MS: calcd. mass for (C31H33N3O7)+ 
560.2398, found 560.2537.  1H NMR (300MHz, CDCl3): 0.98 (t, 3H), 1.43 (s, 9H), 1.71 
(m, 3H), 1.97 (t, 2H), 2.15 (m, 1H), 2.27 (m,1H), 2.68 (m, 1H), 2.94 (m,2H), 3.98 
(m,2H), 5.28 (s, 2H), 5.40 (d,1H), 5.68 (d, 1H), 7.21 (s, 1H), 7.68 (t,1H), 7.84 (t, 1H), 
7.95 (d, 1H), 8.24 (d, 1H), 8.41 (s,1H).  13C NMR (75MHz, CDCl3): 8.3, 28.0, 28.2, 
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28.7, 30.9, 51.0, 67.0, 76.4, 79.4, 95.2, 119.5, 128.4, 128.7, 129.3, 129.6, 130.5, 131.1, 
132.3, 146.1, 146.8, 148.5, 153.0, 154.5, 157.2, 167.8, 173.6. 
4.4.3 Synthesis of Inp-CPT (4)  
A solution of 1.01 g 3 (1.80 mmol) was stirred in 20 mL dichloromethane as 20 
mL trifluoroacetic acid was added slowly.  The reaction continued to stir for 3 h and was 
concentrated in vacuo to yield a yellow residue, which was precipitated with methanol to 
yield the TFA salt as a yellow solid. Yield: 0.82 g (1.47 mmol), 82%.  ESI MS: calcd. 
mass for (C26H27N3O5)+ 460.1873, found 460.1827.  1H NMR (300MHz, DMSO-d6): 0.95 
(t, 3H), 1.79 (m, 2H), 2.17 (m, 4H), 3.05 (m, 3H), 3.28 (t, 2H), 5.30 (s, 2H), 5.52 (s, 2H), 
7.06 (s, 1H), 7.72 (t, 1H), 7.87 (t, 1H), 8.14 (t, 2H), 8.70 (s, 1H).  13C NMR (75MHz, 
DMSO-d6): 8.3, 24.8, 25.2, 30.8, 37.7, 42.8, 51.0, 67.0, 76.8, 95.2, 119.4, 128.5, 128.7, 
129.3, 129.6, 130.5, 131.1, 132.3, 146.0, 146.8, 148.5, 153.0, 157.2, 167.9, 172.9. 
4.4.4 Synthesis of BOC-G2-CPT (5)   
A solution of 54 mg of 4 (0.12 mmol) in 1 mL of N,N-dimethylformamide stirred 
as 22 mg second generation chlorotriazine dendrimer 8 (5.7 µmol) was added.  The 
solution continued to stir as 40 µL of N,N-diisopropylethylamine was added to the 
reaction.  The solution then heated to 50 oC for 12 d and was cooled to rt.  The reaction 
was then concentrated in vacuo and the residue was taken up in chloroform and passed 
through a Sephadex LH-20 size exclusion chromatography column.  The purified 
material was dried in vacuo.  MALDI-TOF MS: calcd. mass for (C327H444N84O54)+ 
6399.36, found 6413.79.  1H NMR (300MHz, DMSO-d6): 0.99 (m, 18H), 1.10-2.50 (m, 
245H), 2.75 (br m, 5H), 3.04 (br m, 30H), 3.34 (br m, 12H), 3.57 (br m, 30H), 3.76 (br 
m, 32H), 4.56 (br m, 12H), 5.27 (br m, 12H), 5.37 (br d, 6H), 5.71 (br d, 6H), 7.19 (br 
m, 6H), 7.66 (br m, 6H), 7.82 (br m, 6H), 7.92 (br m, 6H), 8.20, (br m, 6H), 8.38 (br m, 
6H).  13C NMR (75MHz, DMSO-d6): 7.6, 25.0, 25.8, 27.8, 28.5, 31.8, 37.2, 42.4, 42.7, 
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43.1 44.1, 49.9 67.0, 79.0, 95.7, 120.1, 128.1, 128.4, 129.5, 130.6, 131.2, 145.9, 146.3, 
148.8, 152.2, 156.0, 157.3, 164.9, 165.2, 167.4. 
4.4.5 Synthesis of G2-CPT (6)  
A solution of 25 mg of 5 (0.004 mmol) stirred in 2 mL dichloromethane as 1 mL 
trifluoroacetic acid was added.  The solution stirred for 12 h and was concenctrated in 
vacuo.  The residue was taken up in methanol and concentrated three times and used in 
the next step without further purification.  MALDI-TOF MS: calcd. mass for 
(C267H336N84O30)+ 5202.07, found 5204.21.  1H NMR (300MHz, CDCl3): 0.95 (m, 18H), 
1.10-2.50 (m, 245H), 2.88 (br m, 5H), 3.38 (br m, 12H), 3.61 (br m, 62H), 4.30 (br m, 
12H), 5.24 (br m, 12H), 5.35 (br d, 6H), 5.57 (br d, 6H), 7.24 (br m, 6H), 7.64 (br m, 
6H), 7.79 (br m, 6H), 7.93 (br m, 6H), 8.10, (br m, 6H), 8.43 (br m, 6H).  13C NMR 
(75MHz, CDCl3): 8.2, 26.0, 26.8, 28.0, 29.5, 30.8, 37.3, 42.4, 42.7, 43.0 44.1, 50.7 66.9, 
76.5, 95.2, 119.4, 128.6, 129.3, 129.5, 131.0, 131.6, 132.7, 146.1, 146.7, 148.4, 152.8, 
156.0, 157.3, 158.9, 159.3 165.3, 167.8, 173.6.  
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4.4.6 Synthesis of PEG2000-G2-CPT (7) 
A solution of 7.2 mg of 6 (0.002 mmol) in 4 mL dimethylformamide stirred as 
445 mg NHS-mPEG2000 was added to the solution.  Then, 20 µL of N,N-
diisopropylethylamine was added  to the solution and stirring continued for 48h and was 
concentrated in vacuo.  The product was then purified with ultrafiltration using an 
Amicon stirred cell and YM3 regenerated cellulose membrane.  Upon filtration of 
approximately 6 L of water, the retentate was collected and concentrated in vacuo to 
yield a yellow residue. 
4.4.7 MTT Assay  
 Cells were plated at a density of 5,000 cells / well in 96 well plates.  Plates were 
incubated for 24 hours at 37°C.  Cells were treated with Control (DMSO), triton X-100 
(all dead control), CPT, Irinotecan, G2-CPT-PEG2000, G2-CPT, or G2NH2 for 72 hours at 
37°C. Treatment concentrations were as follows: 3% triton X-100 (all dead control), 
CPT (1µM-10mM), Irinotecan (1µM-50mM), G2-CPT-PEG2000 (1µM-1mM), G2-CPT 
(1µM-1mM), or G2NH2 (1µM-1mM).  Cell toxicity was determined using an MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a tetrazole) assay kit 
(Promega).  For this analysis, 15 µl dye was added per well; plates were incubated for 4 
hr at 37°C.  Then a stop solution (100µl) was added and plates incubated for 1 hr at 
37°C.  Wells were mixed to create a uniform color and absorbance was read at 570 nm 
with a reference wavelength of 650 nm.   
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CHAPTER V 
CONCLUSIONS 
 
5.1 Summary 
The use of polymeric architectures as drug delivery vehicles has been a 
burgeoning field of study in the past 20 years.  Polymeric therapeutics have shown great 
potential at improving solubility, blood retention and diseased tissue accumulation of 
small molecule drugs.  Better understanding of human physiology has enabled more 
efficient tailoring of polymer architectures to achieve desired pharmacokinetics for 
treatment of a variety of diseases.  Furthermore, many tumor models show enhanced 
permeability and retention, which promotes accumulation of the polymer at the site of 
the tumor.  Dendrimer architectures possess additional benefits of monodispersity and a 
well-defined multivalent periphery.  
Triazine-based dendrimer architectures have also shown great potential as drug-
delivery vehicles.  The chemoselective reactivity of cyanuric chloride and use of amine 
nucleophiles results in efficient and inexpensive macromolecules.  Various architectures 
have been developed, which improve the therapeutic index of small molecule drugs.  
The development of various architectures enabled us to optimize the synthesis to achieve 
a second-generation dendrimer at the kilogram-scale.  Dichlorotriazine monomer units 
proved to be more reactive than the monochlorotriazine monomer units used in previous 
syntheses.  Iterations of dichlorotriazine monomer addition to the amine terminated 
dendrimer and subsequent capping and deprotection afforded a second generation 
dendrimer with 12 terminal primary amines in greater that 70% yield with over 1 kg of 
product.  This construct was synthesized for under $10/g and opens the door for 
inexpensive polymeric therapeutics. 
Iterations en route to the kilogram-scale second-generation dendrimer affords 
amine terminated dendrimers and poly(monochlorotriazine) dendrimers.  The amine 
terminated dendrimers have previously been utilized as a vehicle for paclitaxel with 
great success.  Interception of the poly(monochlorotriazine) dendrimer with a drug 
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containing a nucleophilic linker offers a new route to functionalization.  This route 
requires fewer steps and allows for a variety of molecules to be attached to the 
periphery.  Our investigation of desferrioxamine B and camptothecin explores the utility 
of this route.  
Desferrioxamine B, an iron chelate, used for the treatment of iron-overload 
suffers from poor pharmacokinetics.  Attachment of DFOB to polymers has shown great 
potential toward improving the therapeutic index of the drug.  In our hands, nucleophilic 
similarities between the amine and the hydroxamic acids create synthetic hurdles, which 
hinder attachment to the dendrimer.  Acylation of the amine of DFOB with isonipecotic 
acid presents a more nucleophilic amine for reaction with the poly(monochlorotriazine) 
dendrimer.  However, solubility precludes this route from being realized.  Synthetic and 
characterization challenges with desferrioxamine B have forced us to abandon further 
attempts to attach DFOB to the dendrimer. 
Camptothecin, however, has proven more successful.  This antineoplastic agent 
has a lone hydroxyl group poised for reactivity with isonipecotic acid as was utilized in a 
similar manner to DFOB.  Reaction of the modified camptothecin with the 
poly(monochlorotriazine) dendrimer affords a macromolecule with six camptothecins 
and twelve BOC-protected primary amines.  Deprotection and subsequent PEGylation 
affords a dendrimer with an approximate molecular weight of 30 kDa.  The PEGylated 
product proves to be more soluble in water than the free drug and wll presumably 
increase the therapeutic index in vivo.  Investigation of each construct in an MTT assay 
provided dose-response curves in both breast and colon cancer cell lines.   
Although the success of camptothecin was not observed with desferrioxamine B, 
this route offers great potential for functionalization with a variety of drugs or molecules 
of interest.  While not all drugs will be successfully introduced on the dendrimer using 
this nucleophilic liners, the ability to investigate this route offers a new facet to the 
potential of triazine-based dendrimers for drug delivery.  
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5.2 Recommendations 
While the kilogram-scale synthesis proved successful, further improvement of 
dendrimer synthesis must be sought.  Great strides have been made from the initial 
synthesis of triazine-based dendrimer, but new routes and new architectures are 
necessary to optimize drug delivery.  New architectures may also overcome the poor 
solubility issues observed with desferrioxamine B. 
The attachment of desferrioxamine B to the dendrimer proved to be unsuccessful, 
but the development of small molecule triazine-based chelates with high-affinity for iron 
may prove to be an inexpensive alternative.  Efficient synthesis of such chelates have 
proven promising as inexpensive alternatives to DFOB.  Successful modification of the 
reported small molecules to allow attachment to triazine-based dendrimers will afford a 
macromolecular construct capable of iron sequestration.  Upon successful synthesis, 
evaluation of the dendrimers for iron binding affinity and competition in the presence of 
other metals will offer insight into the potential use of this construct as a 
macromolecular iron sequestration agent.  Further evaluation in animal models of iron-
overload will then be required to determine the potential of this drug for further clinical 
investigation. 
 With success obtained with camptothecin in two cell lines, improved synthesis 
may potentially be met through the use of azetidinecarboxylic acid as the linker in place 
of isonipecotic acid.  The improved synthesis on large scale will then provide significant 
amounts of construct for more rigorous characterization in a wide range of cell lines.  
Furthermore, the evaluation of this construct in animals bearing human tumor xenografts 
will generate relevant evidence of further clinical potential.     
While the interests pursued here have focused on desferrioxamine B and 
camptothecin, a variety of other molecules with interesting biological and commercial 
applications may be investigated.  For example, the introduction of fluorescent agents or 
radiolabels for imaging with primary amines available for PEGylation or drug loading 
will move our constructs toward theranostics and long-term biodistribution and chronic 
toxicity studies.  Attachment of drugs to the poly(monochlorotriazine) dendrimer and 
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subsequent deprotection produces a cationic dendrimer capable of condensation of DNA 
or RNA.  Successful delivery of genetic material and drug will potentially sensitize cells 
for more efficient drug activity.     
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